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Abstract

REGULATION AND FUNCTION OF MATRIX METALLOPROTEINASE-1 IN
GLIOBLASTOMA MULTIFORME

By Monika Anand, M.Sc

A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University

Virginia Commonwealth University, 2010

Major advisor: Dr Helen L Fillmore
Assocaite Professor, Department of Neurosurgery

Glioblastoma Multiforme (GBM) is an aggressive and fatal cancer of the brain. It is
characterized with augmented morbidity and elusion to therapies due in part to the
incessant infiltration and spread of tumor cells in normal brain. We investigated the
function of Matrix metalloproteinase-1, an important enzyme noted to be responsible for
invasion in other cancers, in GBM and its regulation by epidermal growth factor receptor

xvii

(EGFR) signaling. Previous studies from our laboratory demonstrated elevated levels of
MMP-1 in GBM.

Further studies indicated the involvement of MMP-1 in GBM

invasion.

The GBM cell lines T98G, U251MG and U87MG were used for this study. In
T98G cell lines, inhibition of MMP-1 by siRNA significantly suppressed basal in vitro
invasion without impacting cell viability.

The over-expression of MMP-1 was

accomplished in U251MG and U87MG using the mammalian expression vector, pIRES,
encoding full length MMP-1 cDNA.

The MMP-1 over-expressing U251MG and

U87MG cells exhibited significantly enhanced invasion in vitro with no modification in
the cell proliferation rates.

A majority of GBM patients present defective EGFR signaling due to overexpression, amplification or mutation in the receptor.

MMP-1 is known to be up-

regulated by various stimulatory agents including growth factors. We examined the
regulation of MMP-1 by EGFR activation and observed the induction of MMP-1 after
EGF treatment.

Inhibition of the receptor by pharmaceutic inhibitor treatment and

genetic approaches led to reduction in MMP-1 levels.

We also observed that this

regulation is primarily mediated by the downstream MAPK pathway.

Inhibition of

MAPK and not PI3K pathway resulted in diminished MMP-1 protein levels even in the
presence of EGF.

xviii

These studies demonstrate the importance of the EGFR-MAPK signaling pathway
in the induction of MMP-1 in glioma cell lines. In addition, MMP-1 plays a role in
glioma cell invasion in vitro. These results along with the reports of MMP-1 overexpression in GBM warrant future studies examining the function of MMP-1 in vivo.

xix

CHAPTER 1

GENERAL INTRODUCTION

1

1.1

Brain Tumors – Overview
Brain tissue is composed of two broad classes of cell types-neurons and
glial cells. Although, neurons are considered to be the primary functional
components of brain due to the generation and transmission of electrical impulses,
a large portion of the brain is constituted by glial cells. These cells are of
different types; astrocytes, oligodendrocytes, Schwann cells, ependymal cells and
microglia. Glial cells provide physical support and nutrition to the neuronal cells
(Jessen and Mirsky., 2005; Campbell and Gotz., 2002). A majority of primary
brain tumors arise from glial cells (astrocytes, oligodendrocytes and ependymal)
and are collectively regarded as glioma (Louis et al., 2007; Kleihues and Cavenee,
2000). Primary malignant CNS tumors account for approximately 2% of all
cancers (Buckner et al., 2007). They are the leading cause of death in children
and the third leading cause of cancer related death in adolescents and adults (1534 years of age) (Jemal et al., 2009). The overall incidence rate of all primary
brain and CNS tumors in the year 2004-2006 was 18.71 per 100,000 person-years
with a propensity of slightly increased occurrence in females. The majority of
brain tumors occur in the frontal, temporal, parietal and occipital lobes (CBTRUS
2009 Statistical report).

The occurrence of high grade malignant glioma is ascribable to certain
genetic abnormalities and possibly environmental factors (Bello et al., 1994).
Mutations in the type 1 neurofibromatosis gene (NF1), adenomatous polyposis
2

coli (APC) gene, Patched-1 (PTCH-1) gene and the tumor suppressor p53 (TP53)
gene lead to genetic syndromes that pose a significant risk factor in the
development of brain tumors. In addition to these germline mutations, high-dose
ionizing radiation is a sole environmental factor that is proven to be conducive to
formation of this neoplasm. Ionizing radiation treatment is given to patients
suffering from acute lymphocytic leukemia (ALL) or non-Hodgkin lymphoma
that predisposes them to increased risk of brain tumors especially gliomas
(Buckner et al., 2007).

Other environmental risk factors such as use of

cellphones, head trauma, electromagnetic fields, N-nitroso compounds and
occupational hazards have also been studied but with inconclusive results
(Wrensch et al., 2002).

1.2 Classification
In the nineteenth century, prior to the beginning of the brain tumor
classification system (1920s), all tumors originating in the brain were regarded as
gliomas (reviewed by Ferguson et al., 2005). In 1867, Virchow stated that these
tumors arise from interstitial brain tissue. In 1875, Golgi showed that some brain
tumors are composed of star-shaped neuroglial cells. An extensive, thorough and
organized work on the classification of brain tumors was started by Bailey and
Cushing in 1922 (Bailey and Cushing, 1926). Thereafter, the World Health
Organization (WHO) proposed a new comprehensive classification of neoplasms
3

affecting the CNS based on the cell-origin in 1993. As per the latest WHO
classification (2007), gliomas belong to the neuroepithelial tumors of the CNS,
arising from glial cells.

Gliomas include astrocytoma, glioblastoma,

oligodendroglioma, ependymoma and other neuroepithelial tumors.

The

incidence rate for neuroepithelial tumors is 1.4 times higher in males than in
females (CBTRUS, 2009)

In addition to laying out a classification for brain tumors, WHO has also
defined a grading system for gliomas that is based on certain histological markers;
increased cellularity, cell proliferation, angiogenesis, necrosis and mitosis. The
tumor grades increase with progressive cell proliferation and necrosis. Grade I is
a low grade brain tumor, regarded as astrocytoma and it is well circumscribed,
therefore considered relatively benign, affecting children and young adults.
Eighty percent of patients with Grade I tumors survive greater than 20 years.
Grade II is a low grade diffuse astrocytoma that grows slowly but has an inherent
tendency to invade normal brain tissues and eventually progress to Grade III and
IV. The median survival rate is highly variable; between five to ten years. Grade
III (Anaplastic astrocytoma) demonstrates histological evidence of malignancy,
including nuclear atypia and accelerated mitotic activity. Grade IV (Glioblastoma
Multiforme, GBM) tumors are malignant, characterized with hyper-cellularity,
profound vascular highly active at mitotic level, necrotic with extremely poor
prognosis and fatal outcome (Louis et al., 2007). Overall, gliomas account for
4

33% of all tumors, of which glioblastomas are the most common, contributing
54% [Figure 1.1].

Figure 1.1

A major portion of primary brain and CNS tumors is

comprised of non-malignant meningioma (~34%) followed by glioblastoma
(~17%). Gliomas are tumors arising from glial cells and include astrocytoma,
glioblastoma, oligodendroglioma, ependymoma, mixed glioma, malignant glioma
NOS (not otherwise specified) and other rare types (CBTRUS, 2010). This figure
shows the distribution of these various subtypes of gliomas (N=50,240). GBMs
are predominantly represented in glioma (53.4%).

The astrocytoma and

oligodendroglioma together constitute 29% followed by small percentages of
ependymomas and mixed gliomas. (CBTRUS Statistical Report, 2010, NPCR
and SEER data from 2004-2006) NPCR= National Program of Cancer Registries.
SEER=Surveillance, Epidemiology and End Results.
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The incidence of glioma is higher in males (7.06 per 100,000 person
years) as compared to females (4.96 per 100,000 person years).

1.3 Symptoms and Diagnosis
General symptoms associated with brain tumors may include headache,
memory loss, cognitive impairment, seizures, visual, speech and sensory deficits,
nausea and vomiting (Chang et al., 2005). Headaches tend to vary in intensity
and are more frequent and severe in the morning.

Seizures are presenting

symptoms in patients with supratentorial tumors. Depending on the location of
the tumor, the signs and symptoms vary. For example, in patients with tumors
located in the parietal lobe, speech dysfunction and sensory loss are observed.
Vision dysfunction may be the outcome of tumors in parietal or occipital lobe.
Temporal lobe tumors are characterized by memory loss and behavioral changes.
A tumor in the frontal lobe could lead to imbalance, speech deficits, seizures
and/or dementia.

Lack of muscle coordination is observed in patients with

cerebellar tumors (Newton, 1994).

Thus, a person presented with persistent

headache with nausea, vomiting or seizures is normally evaluated for the presence
of a tumor mass in brain.

Currently, a variety of imaging methods are being used to assess tumor
mass, extent, localization and malignancy level. Computer tomography (CT) scan
7

and magnetic resonance imaging (MRI) technology reveal most of the anatomical
information such as the size and location of the tumor.

MRI also gives us

information on mass effect, edema, necrosis and hemorrhage at high tissue
contrast. Although, both CT and MRI images are of high spatial resolution, it is
the MRI that delivers better resolution. MRI gives us a sequence of different sets
of images of a brain tumor, each using a particular parameter- T1-, T2-, proton-,
perfusion-weighted images. On a T2-weighted scan, water and fluid-containing
tissue is bright and thus, edema can be seen on a T2-weighted scan as a bright
region.

An improvisation on T2-wighted scan is FLAIR (fluid attenuated

inversion recovery) that separates water (dark) from edematous tissue (bright).
Most brain tumors are hypotense on T1-weighted images and hypertense on T2weighted, FLAIR images. In GBM, the blood brain barrier (BBB) is disrupted
leading to the leakage of the contrasting media [such as gadolinium (Gd)] that can
be seen as a contrast enhanced region. Thus, MRI with gadolinium is considered
to be the better diagnostic tool for confirming a diagnosis (Jacobs et al., 2005).

There have been additions and improvisations in MRI technology that help
a surgeon tremendously. Dynamic contrast-enhanced MRI assesses the vascular
hyperpermeability of tumor vessels thereby helping a surgeon make predictions
for tumor grade. Magnetic resonance spectroscopy (MRS) and positron emission
tomography (PET) are other important tools that are being used to examine the
molecular and metabolic tumor markers in heterogeneous tumors such as GBMs.
8

The imaging is followed by histopathological examination of tumor samples taken
from the patient. Confirmation of tumor grade is made only after histological
analysis of the tumor specimens is complete.

Glioblastoma Multiforme is the most aggressive and invasive tumor of all
the CNS tumors and constitutes approximately half of the gliomas. The hallmarks
of GBM that set them diagnostically apart from low grade gliomas are increase
cellular proliferation, angiogenesis and pseudopallisading necrosis (Kleihues and
Cavenee, 2000). Moreover, the invasive nature of this tumor renders surgical
resection as a merely palliative treatment. Inevitably, the tumors recur due to the
infiltration of tumor cells in a diffused manner to normal tissue. These recurring
tumors are also highly resistant to therapies.

The average age of GBM diagnosis is approximately 55 years. The
diagnosis is made using MRI scans (using gadolinium) of patients with GBM that
show a ring-enhanced mass lesion with low signal intensity at the center.
Thereafter, biopsy is conducted that confirms increased necrosis in the center and
augmented vascularity in the ring-enhanced region. The surrounding region is
composed of normal brain parenchyma that is being diffused with infiltrative
tumor cells.

9

GBMs are categorized into either primary (de novo) or secondary glioma.
In a general population, approximately 90% of the patients are presented with denovo GBMs (Ohgaki and Kleihues, 2007). Primary glioblastomas are typically
diagnosed at a terminal stage without any presence of a previous clinical or
histopathological evidence of pre-existing less malignant lesion. The average age
of patients with de-novo GBM is 62 years. Secondary glioblastomas develop
gradually from a low grade diffused astrocytomas (Grade II) or Grade III
anaplastic astrocytoma and are diagnosed in younger people (average age 45
years). These factors notwithstanding, the clinical outcome of a patient with GBM
does not differ between primary or secondary GBMs. However, there are distinct
molecular and genetic pathways in the development of primary and secondary
GBM (Ohgaki and Kleihues, 2007). These pathways may have some impact on
patient‟s outcome and response to therapy. Thus, studying these molecular events
that lead to the genesis of GBM may help predict the outcome of a patient.

1.4 Treatment
1.4.1 Surgery
GBM poses greatest challenges to a physician due to its highly aggressive
invasive pattern and resistance to therapies. Factors such as neurotoxicity after
therapy, edema due to tumor capillary leakage resulting in intracranial
hypertension and drug delivery complications due to blood-brain barrier make this
10

tumor highly difficult to treat.

Surgery, radio- and/or chemotherapy are the

mainstay treatment options in GBM. Grade I tumors are largely treated with
surgical resection only whereas the treatment options in low grade astrocytoma
vary from patient to patient. The clinical prognosis for Grade III and IV tumors is
extremely poor, with Grade III anaplastic astrocytoma having median survival of
two to three years and Grade IV GBM, a dismal ten to twelve months ( Davis et
al., 1999).

At the initial stages of treatment after GBM diagnosis, resection of the
tumor by surgery is carried out based on the tumor location and its extent.
However, the aggressive infiltration of the GBM tumor cells makes complete
surgical resection of the tumor unachievable. In any case, surgical debulking of
the tumor is vital for relieving intracranial pressure due to tumor mass and
improving survival (Hentschel et al., 2003). Thus, surgery largely remains an
important palliative procedure. It is important to note that complete resection is
defined as the absence of contrast- enhancing tumor image seen on a
postoperative MRI. Conclusions from a recent phase III control trial reveal that
complete surgical resection could be obtained by performing fluorescence-guided
resections with 5-aminolevulinic acid (ALA) – induced tumor fluorescence as
compared to the conventional microsurgery (Stummer et al., 2006).

11

1.4.2 Radiotherapy
After surgical resection, the patients are analyzed for their general health.
A conclusive plan and individual regimen of radio- and chemotherapy is decided
upon. A better prognosis is obtained if a patient is young, has a high Karnofsky
Performance Status (KPS), a high score on Folstein test and has promoter
methylation of the O6 methylguanine methyltransferase (MGMT) gene. KPS is a
scale that runs between zero (death) to 100 (disease-free state) and is based on
parameters such as ability to take care of oneself, requirement of medical care,
progression to disease etc. The Folstein test is a questionnaire that assesses a
patient‟s performance in arithmetic, memory and orientation. MGMT is a repair
enzyme that is involved in the GBM pathology. Methylation of the promoter
region of MGMT inhibits the enzyme and improves prognosis in some patients
(Krex et al., 2007; Esteller et al., 2000; Hegi et al., 2004). Radiation treatment
has been consistently used as part of adjuvant therapy after it was established that
it increased the median survival time from 4 months to 10 months (Walker et al.,
1979). Varying doses, fractions and time interval between the fractional doses of
radiation have been examined for best efficacy. The aggressive growth pattern in
GBM along with the lack of sufficient blood supply makes the tumor environment
largely hypoxic and necrotic. These conditions make the tumor highly resistant to
radiation therapy (Mehta et al., 2004). To circumvent this issue, many radiosensitizers have been tried, including misonidazole and metronidazole, without
any positive results (Mehta et al., 2004).
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Radiation treatment can be given externally (external beam radiation) or
internally (brachytherapy).

Brachytherapy involves placement of radioactive

sources inside the body at or near the resection site. Patients with GBM are
generally treated with external beam radiation; conventional and/or stereotactic.
In conventional external beam radiation treatment, a single beam of radiation is
delivered to the patient in multiple directions to target the tumor volume from all
the sides. Radiation toxicity to nearby healthy tissues is a disadvantage to this
procedure. Stereotactic radiation treatment involves delivering a high dose of
radiation directly to the tumor/resected area in a single or two to three sessions.
This type of radiation treatment minimizes the death of healthy tissue, requires
lesser time, is equally or more effective but it is suitable to only small, well
defined tumor masses (Buckner et al., 2007).

The standard external beam

radiation treatment consists of 25-35 daily treatments for over five to seven weeks
for a total radiation dose of 60 Gys (Chandana et al., 2008). In patients above 70
years of age, a total of 50 Gys with 1.8 Gy fractions has been found to improve
survival outcome (Keime-Guibert et al., 2007).

1.4.3 Chemotherapy
Studies in finding appropriate drugs for brain tumors have been ongoing
for the past 30 years with very limited breakthroughs.

Carmustine (BCNU)

chemically 1, 3-bis (2-chloroethyl)-a-nitrosourea, was the first single drug used in
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the treatment of malignant glioma in early 1970s (Barker et al., 1973; Wilson et
al., 1976).

In majority of patients, BCNU used to be given to patients

intravenously but nausea and vomiting were experienced by patients within 2
hours of infusion. An improvised version of BCNU delivery method, Gliadel
wafers, was developed (Wu et al., 1994). These small wafers coated with BCNU
were placed directly to the site of tumor. However, this method too has its own
complications.

There was risk of toxicity to adjoining healthy tissues and

decrease in blood count making the patient susceptible to infection and bleeding.
Moreover, it was costly for most of the patients. Concurrently procarbazine was
also developed and has been used in the clinical trials (Kumar et al., 1974). Over
a period of time, due to dismal improvement in survival, multidrug treatments
were initiated.

The drug combination procarbazine, CCNU (lomustine) and

vincristine (PCV) was found to be highly effective (Gutin et al., 1975). However,
this therapy was accompanied with extremely severe side effects. Advent of
Temozolomide (TMZ) (Figure 2) was a breakthrough in the chemotherapeutic
treatment of GBM patients. TMZ (Temodar; Schering-Plough, Kelinworth, NJ) is
an alkylating agent that induces methyl-groups at N-7 or O-6 positions of the
guanine residues in DNA. Due to the damage to DNA, there is considerable cell
death and tumor growth control.

TMZ is very stable at acidic pH but its

degradation increases between neutral to basic pH. The drug is administered in its
pro-form and during physiological pH, it rapidly degrades and becomes activated.
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Figure 1.2. Chemical structure of Temozolomide

Upon hydrolysis in the physiological pH, the TMZ ring structure collapses
releasing N2 from (N at positions 2 and 3), CO2 gas (C-4), 5-aminoimidazole-4carboxamide (AIC) (N-1 and imidazole atoms), a natural component of urine, as
by-products. The methyl group transfer takes place immediately after reaction
with water/hydroxyl group.
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Although there is considerable cell death due to TMZ, tumor cells may
develop resistant mechanisms to it by expressing repair enzymes such as the
above mentioned O6-methylguanine-DNA methyltransferase (MGMT) gene.
TMZ induced methyguanine adducts are removed by MGMT as part of repair
process. This MGMT-mediated resistance to TMZ is overcome by pre-treatment
with O6-benzylguanine; a substrate analog for MGMT. TMZ itself is also used as
a pretreatment to deplete the levels of MGMT in tumor cell population (Tolcher et
al., 2003).

Clinical trials using TMZ have shown that it can be regarded as an oral
single-agent drug superior to other drugs for recurrent GBM patients (Yung et al.,
2000).

Recently, the European Organization for Research and Treatment of

Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) performed
a randomized, multicenter, phase III trial to compare radiotherapy with TMZ as
adjuvant followed by TMZ treatment for six months and radiotherapy alone. The
patients with TMZ plus radiotherapy had a higher 2-year survival rate and
increased progression-free survival as compared to the radiotherapy alone (Stupp
et al., 2005).

Such studies have made TMZ administration and fractionated

radiotherapy following near complete surgical resection of tumor as the standard
care in the treatment of GBM patients today.
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Despite latest revolutionary surgical tools, newer and better methods of
drug delivery, the disease is incurable and has very high morbidity rate. New
insights into the glioma molecular biology may provide hope. As stated earlier,
GBM is a heterogenous tumor with dysregulation of multiple signaling pathways
due to genetic mutations. Using glioma biology as basis, new chemotherapies are
underway. Most of these therapies target molecules that are involved in growthfactor mediated cell-signaling pathways that lead to increased cell proliferation
and neo-angiogenesis.

1.5 Glioma Biology
As mentioned above, GBMs either develop de-novo, without any previous
manifestation of the disease or they progress from low-grade astrocytomas. The
important genetic alterations that lead to GBMs are listed in Table 1. GBMs are
characterized by loss of heterozygosity (LOH) at chromosome 10q, epidermal
growth factor receptor (EGFR) amplification, mutation or over-expression,
p16INK4a deletion and loss or mutation in phosphatase and tensin homolog
(PTEN).

During development into secondary glioblastomas from low grade

astrocytomas, the most characterized genetic alteration is mutation in TP53. This
is followed by accumulation of other additional genetic mutations such as
alterations in retinoblastoma protein (RB) gene, PDGF and PDGF-α overexpression, LOH at chromosome 19q and 10q and PTEN mutations. The primary
17

and secondary GBM also differ in the promoter methylation patterns and RNA
expression profiles (Ohgaki and Kleihues, 2007). In addition, the DNA repair
mechanisms that go awry in GBM include nucleotide excision, base excision and
mismatch repair mechanisms. As mentioned earlier, MGMT is a mismatch-repair
enzyme that helps in protecting a cell from alkylating agents generated by
environmental damage. In addition, MGMT also imparts cancer cells a resistance
mechanism to chemotherapeutic drugs that induce cell death by acting as DNAalkylating agents.

In a subset of GBM patients, MGMT gene is hyper-

methylated. In these patients, treatment with DNA-alkylating drug has better
prognosis (Nagarajan and Costello, 2009).
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Table 1- Genetic Events in GBMs

19

Aberrant RTK (receptor tyrosine kinase) (EGFR, PDGFR, MET) signaling
together with hyperactivated downstream pathways including RAS/MAPK,
PI3K/AKT/mTOR, Protein kinase C (PKC) signaling, depletion of p53 and
defects in RB pathway contribute significantly to glioma growth, proliferation,
survival, vascularization and invasion in GBMs (Grzmil and Hemmings, 2010)
(Figure 3). Amplification and over-expression of EGFR is more common in
primary GBMs than secondary GBMs. EGFR amplicons are often mutated, with
EGFRvIII mutation (deletion of exon two to seven), as the most prevalent form.
The EGFRvIII variant is a constitutively active form of the receptor. This type of
mutation has profound effects on cell proliferation, migration and vascularization.
In addition, this truncated receptor also confers resistance to chemotherapeutic
agent, cisplatin by modulation of BcL-xL and caspases in cell death pathways
(Nagane et al., 1998).

In a vast majority of malignant brain tumors, including GBM, mutations in
the TP53 pathway and/or retinoblastoma (RB1) pathway are also prevalent. TP53
mutations are the hallmark event in secondary GBMs. They also occur in primary
form of GBM, although at a lower frequency (<30% of the cases, Ohgaki et al.,
2004). Mutation pattern involving G: C → A: T, frequently at two hotspot codons
248 and 273 in TP53 gene, are directly associated with progression to secondary
GBMs. In GBMs, where TP53 mutation is absent, there is an amplification of
MDM2 (murine double minute) that rapidly degrades TP53 protein (Biernat et al.,
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1997). TP53 protein gets activated after DNA damage in response to radiation or
chemical mutagens.

MDM2 binds to TP53 facilitating its degradation by

ubiquitinization. Conversely, MDM2 gene is up-regulated by TP53. In normal
cells, this regulatory feedback loop is maintained but in a transformed cell, this
regulation is dysfunctional. Another gene product, p14ARF binds to MDM2 and
prevents MDM2 –mediated degradation of TP53. Thus, loss of TP53 function, in
a tumor cell, may result from aberrant expression in MDM2 and p14ARF gene.
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Figure 1.3 Major pathways in gliomagenesis Schematic representation of
EGFR signaling in glioma. Epidermal growth factor binds to its receptor EGFR
leading to receptor dimerization and autophosphorylation at various tyrosine (Y)
residues.

This further results in activation of several downstream signaling

pathways among them ras-raf-MAPK, PI3K/AKT and JAK/STAT are prominent.
MAPK activation affects DNA synthesis and cell proliferation and PI3K/AKT has
role in cell survival.
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RB1 (retinoblastoma 1) pathway is equally dysregulated in both primary
and secondary GBMs. RB1 protein is phosphorylated by the CDK4/cyclin D1
complex releasing E2F transcription factor which induces genes that aid in G1→S
transition in the cell cycle. Another important protein, p16INK4a binds to CDK4
and inhibits RB1 phophorylation, thus inhibiting the G1→S transition.

Loss of heterozygosity (LOH) at chromosome 10q is a major genetic
alteration that occurs in 60-80% population with GBMs (Fujisawa et al., 2000,
Rasheed et al., 1995). As an exclusive event, complete loss of chromosome 10
may be seen only in primary GBMs. The commonly deleted loci at chromosome
10 are 10p14-p15, 10q23-24 (PTEN) and 10q25-qter that encodes several tumor
suppressor genes.

Promoter methylations of the p14ARF, p16INK4a, RB1, MGMT and tissue
inhibitor of metalloproteinase-3 (TIMP-3) genes are common events in secondary
GBMs (Nagarajan and Costello, 2009).

In a cDNA expression profile study

conducted to assess differences in gene expression, IGFBP2 gene was
significantly over-expressed in primary GBM (Godard et al., 2003). Microarray
analysis with subsequent gene annotation revealed alterations in genes involved in
cell cycle regulatory pathways in secondary GBM and loss of function in genes
involved in signaling pathways in primary GBMs (Tso et al., 2006). EGFR,
MDM2 and MMP-9 genes were elevated in primary GBM as observed from both
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arrays and immunohistochemistry profiles (Watanabe et al., 1996; Tso et al.,
2006; Biernat et al., 1997).

1.5.1 Glioma Biology as basis for developing novel drug targets
GBM treatment remains unfruitful due to numerous factors that include
lack of effectiveness and high cytotoxicity of the drugs, aggressiveness of the
disease and inability for complete surgical resection of the tumor. These pitfalls
in the therapy have led to the development of novel drugs that target cellular
signaling pathways in gliomagenesis. GBM is a heterogeneous tumor wherein
multiple signaling pathways are dysregulated.

Targeting different molecules

simultaneously is important for a successful outcome. In tumor cells, several
diverse signaling pathways are constitutively active. Some of these pathways
converge to common downstream transcriptional factors. Developing a drug
against a target upstream in a signaling pathway would not be as beneficial as
developing multiple downstream targets because inhibition of upstream molecules
in a signaling pathway may result in other compensatory mechanisms leading to
drug resistance.

Some of the small molecule inhibitors that seem promising are inhibitors
that target EGFR (erlotinib), Akt (perifosine), farnesyl transferase (lonafarnib),
Met (XL184), mTOR (sirolimus), PI3K (BEZ235), PDGFR (imatinib) and TGF-β
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(AP12009).

A complete comprehensive list of inhibitors to such oncogenic

molecules is given in Table 2 (Adamson et al., 2009). The anti-angiogenesis
approach has been significant with regards to GBM because aggressive growth of
the tumor leads to hypoxic conditions that in turn cause neovascularization.
Recently the developed anti-angiogenic drug, Bevacizumab, a monoclonal
antibody against vascular epidermal growth factor (VEGF) has been FDA
approved in 2008 for use in breast cancer patients. This drug is a strong candidate
for GBM patients and is under clinical trials for GBM therapy (Adamson et al.,
2009). Other anti-angiogenic drugs under clinical trials for GBM are the ones that
target αvβ5 integrins (cilengitide), hepatocyte growth factor (HGF) (AMG-102)
and VEGFR (sunitinib) (Adamson et al., 2009).
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Table 2 Current active clinical trials for GBM in United States (Adamson et
al., 2009, www.clinicaltrials.gov).

The most common chemotherapies under

investigation include small-molecule targeted therapies (directed against
molecules in signaling pathways), anti-angiogenic therapies, immunotherapies
and gene therapies. The drugs listed here are primarily against the molecues
aberrantly activated or over-expressed.
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Immunotherapy
In addition to above therapies, another promising approach is using
immunotherapy where patients own immune system is used to target the tumor
cells (Kanaly et al., 2010). Injections of tumor peptides by RNA, DNA, Viral
particles or whole cells leads to sensitization of these lymphocytes against a tumor
antigen leading to specific clearance of tumor cells without affecting the normal
healthy tissue. For example, TP-38 is a genetically engineered protein that has
the EGFR ligand (TGF-α) fused with pseudomonas exotoxin. The N-terminus of
TGF-α protein binds with EGFR followed by TP-38 exotoxin cleavage and cell
death (Rainov and Soling, 2006).

In the passive approach of immunotherapy, the lymphocytes are removed
from a patient‟s body, expanding those cells that demonstrate activity against the
tumor cells and reintroducing them back in the patient. For example, dendritic
cells (DCs) are loaded with tumor specific peptides (EGFRvIII), tumor lysates,
tumor stem cell mRNA and injected into the GBM patient as vaccines (Parney et
al., 2000). In one such Phase I clinical trial of DC immunotherapy, survival was
prolonged to 133 weeks as compared to 33 weeks in control patients and the
therapy was found to be completely safe (Yu et al., 2006). In a more tumorspecific target approach, EGFR vIII vaccine has been developed and has delivered
promising results in two separate clinical trials (Schmittling et al., 2008; Parney et
al., 2010).
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Brain Tumor Stem Cells
During developmental stages, mammalian brain contains a population of
neural stem cells (NSCs) that have the capacity to self-renew and proliferate. The
presence of such NSCs in adult human brain has been reported in separate studies
(reviewed by McKay 1997; Uchida et al., 2000). These NSCs gained great
significance in CNS repair mechanisms post-injury (Laywell and Steindler, 2002).
Presence of neural progenitor cells in adult brain strongly links normal
physiological development of brain with brain cancer (Pardal et al., 2003).

Recently, brain tumor stem cells (BTSCs) have been identified and
isolated from brain tumor specimens from patients by using a neural stem cell
marker CD133 (Ignatova et al., 2002; Singh et al., 2003, 2004). These CD133+
BTSCs show high capacity to self-renew and proliferation in-vitro and in-vivo.
The CD133+ tumor neurospheres express stem-cell marker, nestin during neural
stem cell culture conditions and upon changing culture conditions to serumcontaining media, they differentiate into a mixed population of neurons,
astrocytes and oligodendrocytes.

More recently, it has been reported that

isolation of CD133- cells from GBM also form orthotopic tumors in mice and
give rise to CD133+ cells in vivo (Wang et al., 2008). This suggests that there
may be other tumor initiating cells in GBM that do not express CD133.
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Understanding the biology and gene expression profile of BTSCs would
provide means to test novel therapeutics strategies. Prominent signaling pathways
that are vital for survival of BTSCs are PI3K, NOTCH, Wnt, SHH.

These

pathways are needed to be targeted for elimination of BTSCs from tumors.
Another approach would be to promote differentiation in BTSCs as it has been
found that using bone-morphogenic proteins (BMPs) induced differentiation and
prolongs survival in mice models (Atkinson et al., 2009, Hadjipanayis et al.,
2009).

1.6 Invasion

1.6.1 General overview of Invasion and metastasis in cancers
other than GBM
In any cancer setting, tumor cell invasion and metastasis dramatically increase
the morbidity and mortality due to cancer. To achieve invasive properties, a
subpopulation of tumor cells must recognize the ECM molecules present in the
vicinity of the cell, attach to these molecules by specific receptors present on the
cells and modify the ECM by cleaving physical barriers paving a way for the
tumor cell to migrate to other parts of the body (Geho et al., 2005).
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Figure 1.4: Invasion/Metastasis in cancer
Invasion process has three basic steps:
a) The tumor cells detach from the solid tumors at the site of origin.
b) The cells then adhere to the extra-cellular matrix (ECM) proteins by
expressing specific receptors that bind to ECM proteins.
c) The cells release proteases and other molecules that aid in the degradation of
complex ECM molecules thereby paving a way for the tumor cell to navigate
through adjoining normal tissue.
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Following invasion through ECM and blood vessels, the tumor cells
migrate and attach to a new location. The new tumor mass is formed by upregulating complex molecular machinery that aids in the process of proliferation,
growth and neo-angiogenesis. These molecular mechanisms are similar to the
ones that aid in normal physiological growth. During normal development, the
cellular migration is tightly controlled by organism‟s homeostasis. In contrast,
during metastasis, there is an unchecked constitutive up-regulation of molecular
mechanisms that eventually leads to the death of the organism.

At the initial phase of the invasion process, interaction between tumor
with ECM and stromal cells (Liotta et al., 2001) are mediated by cell-cell, cellECM contact and secretion of soluble factors by tumor cells that interact with
ECM and stromal cells. The cell-cell and cell-ECM contacts are made by special
class of adhesion receptor family of proteins that include selectins, immunoglobin
cell-adhesion molecules, cadherins and integrins. The most widely studied cell
adhesion receptor protein is integrin family of receptors.

Integrins are

heterodimeric transmembrane proteins that bind to specific ECM molecules at the
extracellular side and specific cytoskeletal (CSK) adaptor proteins intracellularly
(Giancotti and Ruoslahti, 1999) such as focal adhesion kinase (FAK) (Guo and
Giancotti, 2004). In normal physiology, when a cell is detached from the ECM, it
does not survive, a process referred to as “anoikis” (Frisch and Ruoslahti, 1997).
Tumor cells escape anoikis by activating PI3-kinase/AKT pathway that inhibits
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caspases (Frisch and Ruoslahti, 1997).

Ligand binding to integrins leads to

integrin-clustering and recruitment of intracellular signaling components
following which Rho family of GTPases, MAP and PI3-kinases activate.
Receptor tyrosine kinases, integrins and G-protein coupled receptors co-ordinate
and get activated during tumor cell‟s transformation to a migratory and invasive
phenotype.

Cytoskeletal changes like actin-polymerization and myosin-

contraction are mediated by Rho-kinases and cause polarization of the cell,
membrane extension and cell substratum attachment in the migration process.

Tissue remodeling by matrix degradation and turnover are important
events during physiological development. These events are also an integral part
of wound healing, tumor necrosis and inflammation.

The most important

enzymes that are at the forefront of matrix degradation are matrix
metalloproteinases (MMPs). Due to the proteolytic activity of MMPs, the rigid
barriers of ECM are removed, latent forms of growth factors, proteases and
chemotactic agents are activated and bioactive molecule within ECM are
generated. In addition, the integrin binding sites in the ECM become exposed to
interact with cells for transmitting migratory and survival signals (Davis, 1992).

35

1.6.2 Invasion in Glioblastoma Multiforme (GBM)
One of the important underlying reasons for the failure of GBM therapies
is the ability of GBM cells to invade local brain parenchyma. Maximal surgical
resection only slightly helps in improving patient‟s outcome as by the time the
disease is diagnosed; tumor cells may have already infiltrated and cannot be
identified. Thus, there is a dire need for therapeutic approaches that target the
invasion process in GBM (Davis and McCarthy, 2001).

Brain tumor cells follow the basic steps of invasion with the unique
exception that they rarely invade outside the brain tissue and metastasis by GBM
cells is confined to within the brain tissue. There is no invasion and extravasion
in and through the vasculature (Burger and Scheithauer, 1994; Hunter et al, 2003;
Kleihues and Cavenee, 2000). The invasion pattern followed by primary brain
tumors is different from the tumors that metastasize to the brain from other parts
of the body. Primary brain tumors invade aggressively to wider margins within
the brain, generally as single cells, some have the tendency to invade along the
periphery of blood vessel walls or along white matter tracts in Virchow-Robins
space (Fillmore et al., 1999; Bellail et al., 2004). These findings suggest that the
migration of invading cells is dependent on specific substrates present in the
microenvironment of CNS. Metastatic tumors that invade to brain generally have
a well-defined mass and invade as groups of cells. Thus, a metastatic brain tumor
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has relatively better response to surgical resection as compared to a primary
malignant brain tumor.

Various studies have been conducted to study the migration pattern of
GBM cells (Swanson et al., 2000, 2003; Mandonnet et al., 2003; Harpold et al.,
2007). These studies are based on in-vitro experimental models (tumor spheroids)
of tumor invasion and suggest that various patterns of migrations are followed by
GBM cells including isolated islands, branching and dispersion both near and
away from the tumor boundary.

These results have been corroborated by a

mathematical model based on partial differential equations (PDEs) that use
glioma cell density and concentration of nutrients, proteases such as MMPs and
ECM (Kim et al., 2009). It was shown that different dispersion patterns arise from
the differences in haptotactic, chemotactic and cell-cell adhesion factors. The
chemotactic flux is generated when tumor cells get attracted to glucose for energy
requirement (Warburg effect) and move in the direction of glucose gradient. The
model was based on the consideration that brain ECM is a deformable mass of
fibers that is constitutively being degraded and remodeled by MMPs. Using this
model, they observed that increasing cell-cell adhesion forces slowed migration
confirming earlier reports of requirement of loss of cell-cell contacts for invasion
in T98G cells (Perego et al.,2002).
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ECM in brain mainly consists of hyaluronan, proteoglycans, tenascin-C
and thrombospondin. Due to low abundance of fibrillar collagen, laminin and
other molecules that impart strength to the ECM, it is largely amorphous and
loosely bound and therefore difficult to study (Chintala et al., 1996).
Proteoglycans such as chondroitin, heparin sulphates and glucosaminoglycans
(GAGs) are present in brain parenchyma (Chintala et al., 1996).

Other

proteoglycans present in the brain are hyaluronic acid (HA), tenascin and
cytotactin (Table 3).

Table 3: Components of ECM in brain (Adapted from Chintala et al., 1996)
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The components of ECM continuously change during development and diseased
states modulating brain cell growth, differentiation and invasion by different
mechanisms. Hyaluronic acid (HA) is increased several fold in primary brain
tumors comparable to the levels present during developmental stages of the brain.
HA has been regarded to be involved in facilitating the tumor migration and
invasion using specific cell surface receptors, cluster differentiation 44 (CD44)
(Akiyama et al., 2001). Tenascin C is also up-regulated in brain tumors and its
levels correlate with tumor grade (Higuchi et al., 1993; Zagzag et al., 1995). The
expression of type IV collagen and laminin has also been reported to be found in
the vessel walls along the endothelial glomerulus-like proliferations (Bellon et al.,
1985). Type V collagen and fibronectin is present in vessel walls in the basement
membrane and perivascular matrix and type 1 and III collagens are observed in
the vessel walls and perivascular connective sheet (Bellon et al., 1985).

1.7 Matrix Metalloproteinases (MMPs)
1.7.1 Nomenclature and Classification
MMPs are a large family of zinc-dependent endopeptidases that
collectively have the ability to cleave every component of ECM.

The first

member of the family, MMP-1, also referred to as collagenase-1, was described
by Gross and Lapiere in 1962 while studying tadpole morphogenesis (Gross and
Lapiere, 1962). Since then, 23 members of the MMP family have been found to
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be expressed in human.

MMPs play a crucial role in normal physiological

processes like tissue remodeling during embryonic development (Page-McCaw et
al., 2007), wound healing (Parks et al., 2004) and cancer (Egeblad and Werb,
2002). Historically MMPs have been divided into four categories depending on
their

substrate-specificites:

Collagenases,

Gelatinases,

Stromelysins

and

membrane-type MMPs (MT-MMPs) (Table-4). Collagenases act on collagens
type I, II, III, fibrillar collagens type I, II, III, VI, IX and include MMP-1, -8 and 13.

MMP-18 is also a collagenase found in Xenopus species but it is not

expressed in humans. There are two groups within gelatinases- Gelatinase A
(MMP-2) and Gelatinase-B (MMP-9). Their primary substrate is gelatin type I,
II, III but they can also act on collagen type IV, V, VII, X, fibronectin and elastin.
Stromelysins are also divided further into three subgroups- stromelysin 1, 2 and 3.
They act on fibronectin, laminin, collagens type II, IV, V, IX, gelatin type I, III,
IV, V. Stromyelin 3 (MMP-11) is a unique enzyme that does not cleave ECM
molecules such as collagen, laminin, elastin and fibronectin.

Most of the

membrane-type MMPs cleave progelatinase-A. These membrane-tethered MMPs
are important for regulating cell behavior as they influence cell-surface and ECM
activity. The secreted MMPs also aid in the signaling mechanisms by cleaving
latent growth factor molecules in the ECM. In addition, they can also bind to the
integrins or CD-44 cell surface receptors. Each member protein is encoded by a
different gene and most of the genes for MMPs are clustered on chromosome 11
indicating a common evolutionary origin. The region Ch11q23, where MMP
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genes are localized, is found to be amplified in several solid tumors (Rooney et
al., 1999).

The MMPs now are categorized on the basis of their structure

(Egeblad and Werb, 2002)
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Table 4: Nomenclature and Substrate specificities of MMPs
(Adapted from Egeblad and Werb, 2002)
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1.7.2 Structure
Structurally, MMPs have distinct domains with some highly conserved
regions.

The MMPs have been divided into eight distinct structural groups

(Figure 4). These groups have a common basic structure called as the “minimal
domain”. The minimal domain consists of an amino terminal signal sequence
(Pre) which is cleaved by the signal peptidase for facilitating the enzyme‟s entry
into endoplasmic reticulum (ER). The Pre-domain is followed by a “Pro” domain
consisting of a thiol group (-SH) and a furin- cleavage site. The pro-domain
connects to a catalytic domain that has a Zn2+ atom binding site. The cysteine
sulfhydryl group binds covalently to the Zn atom in the catalytic domain. This
keeps the enzyme in its latent state. To activate the enzyme, the cystein to Zn
bond has to be disrupted by either normal proteolytic removal of pro-domain by
serine proteases or by ectopic disruption of cystein-Zn interaction (cystein switch)
(Sternlicht and Werb 2001). Intracellular furin-like proteases that target the furinrecognition motifs (Fu) in the catalytic domains can cleave the prodomain and
activate the enzyme intracellularly. The covalent bond can also be disrupted by
chemicals such as amino-phenyl mercuric acid (APMA) or other serine proteases
present in the ECM such as plasminogen activators (PA). In addition to this
minimal domain, simple hemopexin domain containing MMPs have at the Cterminus a hemopexin-like domain that is connected to the catalytic domain by a
hinge (H) region. There is a di-sulfide bond (S-S) between the first and the last
subdomain of hemopexin domain. This hemopexin-like domain mediates the
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interaction of the enzyme with other proteins such as the tissue inhibitors of
metalloproteinases (TIMPs), cell surface molecules and proteolytic substrates.
The gelatin binding MMPs have collagen-binding type II motifs of fibronectin
(Fi) present in the catalytic domain. The furin-activated secretory MMPs have
furin-proteases recognition motifs in their catalytic domain that cause intracellular
activation of these MMPs. Membrane anchored MMPs include MT-MMPs that
have a transmembrane domain at the C-terminus of the enzyme with a small
cytoplasmic domain and glycosylphophatidylinositol (GPI) anchor or an aminoterminal signal anchor (SA). The MMP-23 (Type II transmembrane MMP) has a
unique cystein array (CA) and immunoglobulin (Ig)-like domains (Egeblad and
Werb, 2002).
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Figure 4 Schematic of different structural categories of MMPs
The MMPs have been divided into eight categories based on their structure. All
MMPs except type II MT-MMPs have a pre domain followed by a pro domain
consisting of a thiol (SH) group. Type II MT-MMPs have signal anchor (SA) at
the N-terminus. The catalytic domain has Zn atom binding site (Zn) or cystein
array (CA). Some MMPs have collagen binding type II motifs of fibronectin (Fi)
in the catalytic domain.

The pro-domain may also include furin-proteases

recognition motif (Fu) and Vitronectin (V). The hemopexin domain is connected
to catalytic domain by a hinge region (H). The C-terminus of some MMPs may
have glycosylphophatidylinositol (GPI) anchor or immunoglobulin (Ig)-like
domains. (Adapted from Egeblad and Werb, 2002)
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Figure 4
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1.7.3 Functions of MMPs
The function of MMPs in normal physiological conditions is
controlled and regulated at various levels depending upon the requirement. A
balance is maintained between expression of MMPs and their proteolytic
degradation and inhibition by endogenous inhibitors. ECM is a biologically
active and dynamic tissue that is continuously being remodeled and harbors
various growth factors and signaling molecules. Any changes brought about in
ECM affect cell cytoskeletal, adhesion machinery, growth and differentiation.
Thus, by degrading ECM, MMPs are indirectly influencing these important events
that shape cell behavior.

Functions of MMPs in normal physiology
Although MMPs are traditionally known to have ECM degradation
as their primary function, recent work in MMP biology has shown that these
enzymes can perform their proteolytic function to conduct many important
physiological processes (Page-McCaw et al., 2007).

MMPs can alter the

epithelial tissue architecture by cleaving cell-cell junctions and cleave ECM
molecules to clear the path for cell movement. They can also generate signaling
molecules from ECM that may act by autocrine or paracrine mechanisms. For
example, cleavage of collagen IV α3 chain by MMP-9 yields a new bioactive
molecule, tumstatin, an anti-angiogenic peptide that binds to integrin receptor
(Hamano et al., 2003). MMPs can also cleave latent bioactive molecules altering
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cell behavior.

For example, cleavage of vascular endothelial growth factor

(VEGF) modifies its structure and affects its binding affinity to the receptor (Lee
et al., 2005). MMPs can deactivate a signaling molecule by cleaving it thereby
affecting cellular proliferation and motility. For example, MMP-2 cleaves CXCmotif ligand-12 (CXCL12) and inactivates it thereby making the host more
susceptible to HIV-infection (McQuibban et al., 2001). Cleavage of collagen type
XVIII results in a fragment, endostatin, which is an anti-angiogenic molecule.
MMP-1 and MMP-3 cleave insulin-like growth factor binding protein-3 (IGFBP3) present in ECM releasing IGF bound to it (Fowlkes et al., 1994). MMP-1 and
MMP-3 also degrade proteoglycan perlecan present in ECM to release FGF
(Whitelock et al., 1996).

MMP-1 mediated type I collagen degradation is

necessary for epithelial cell migration and would healing in culture models
(Pilcher et al., 1997).

MMPs also perturb membrane signaling by cleaving growth factors,
tyrosine kinase receptors, cell-adhesion molecules, cytokines, chemokines and
other MMPs. Cleavage of membrane proteins such as E-cadherin and CD44 by
MMPs results in an increase in cell migration and invasion (Noe et al., 2001;
Kajita et al., 2001). Other examples of membrane protein shedding are cleavage
of syndecan by MT1-MMPs resulting in an increased cell migration (Endo et al.,
2003). TGF-β is released from its latent state by membrane localized MMP-9
(Yu and Stamenkovic, 2000).
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MMPs in bone remodeling
MMPs are important in bone development and remodeling.

MMP-9

knockout mice have defects in endochondral ossification, an important step in
bone development (Vu et al., 1998). Although MMP-9 is also found to be highly
over-expressed during bone healing after a fracture, it is not mandatory for
healing process (Colnot et al., 2003). MMP-13 is required for bone remodeling
and the transition from cartilage to bone at the growth plates of long bones
(Stickens et al., 2004; Inada et al., 2004). MMP-14 knockout mice are lethal with
gross defects in connective tissue remodeling (Holmbeck K et al., 1999; Zhou Z
et al., 2000).

Loss of function mutations in MMPs lead to defects in bone

developmental diseases. MMP-2 mutation causes a rare osteolytic syndrome
(Martignetti et al., 2001). Mutations in MMP-20 results in tooth enamel defect
amelogenesis imperfect (Kim et al., 2005). Mammary gland development during
puberty requires MMPs mediated degradation of basement membrane and ECM
for restructuring vascular network (Sternlicht et al., 2006).

MMPs and Vascular development

MMPs mutants do not show any

defect during embryonic vascular development but postnatal vascular remodeling
and angiogenesis is severely affected.

MMP-9 mutants show defects in

angiogenesis at the growth plate of long bones (Vu et al., 1998). MMP-2 mutant
mice show reduced vascular growth (Kato et al., 2001) but MMP-14 mutant mice
lack it altogether (Zhou et al., 2000). Such defects in vasculature could be
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attributed to important functions of MMPs such as proteolysis of type I Collagen,
modification of PDGF and VEGF.

In addition to developmental events, MMPs also contribute in maintaining
cellular balance during inflammation and wound healing (Parks et al., 2004).
MMP-7 mutant mice are more susceptible to bacterial infections due to the
inability of MMP-7 mutant mice to proteolytically cleave and activate
endogenous antibiotic, pro-cryptdin (Wilson et al., 1999). MMP-7 mutant mice
do not show closure of wounds due to absence of MMP-7 mediated cleavage of
E-cadherins (McGuire et al. 2003). Injury and infection produce inflammation by
inducing leukocyte migration towards chemoattractants. The formation of
chemoattractants requires MMP- mediated cleavage of syndecan-1 ectodomain. It
has been found that neutrophil migration is defective in MMP-7 mutant mice due
to the absence of neutrophil attractant CXCL1 (Li et al., 2002). MMPs can act as
both pro-inflammatory by recruiting inflammatory cells (Haro et al., 2000) and
anti- inflammatory by speeding up clearing and removal of inflammatory cells
(Kumagai et al., 1999). MMP-12 contributes to emphysema (Morris et al., 2003)
while MMP-9 is pro-inflammatory in skin (Liu et al., 2005). MMP-8 protects
againt skin inflammation (Balbin et al., 2003) and MMP-2 provided similar antiinflammatory protection in brain and spinal cord (Esparza et al., 2004). Thus,
MMPs regulate inflammation by controlling or inducing it depending on cellular
microenvironment.
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MMPs in pathology
Due to the inherent and primary proteolytic function of MMPs, much
research has been focused on the role of MMPs in diseases that involve the
breakdown of connective tissues like rheumatoid arthritis (RA), osteoarthritis,
periodontitis, inflammation and even cancer. During inflammation, leukocytes,
particularly, macrophages synthesize and store these MMPs. The MMPs released
from macrophages help in the migration, invasion and extravasation of these
leukocytes into the tissues thereby causing tissue damage. In addition, there is a
production of immunogenic fragments of otherwise normal proteins that catalyzes
auto-immune response (Opdenakker and Van Damme, 1992).

MMPs are

involved in gastric ulcerations and impaired intestinal wounds (Vaalamo et al.,
1998). Normal human brain has very low levels of MMPs but these enzymes are
significantly elevated in various neurological disorders of CNS (Yong et al.,
2001). The high levels of MMPs can induce neuro-inflammation, demyelination
of neurons (multiple sclerosis, MS) and disruption of blood-brain barrier with
serious consequences (reviewed by Yong et al, 2001;

Kieseier et al 1999).

Several MMPs are found to be expressed at elevated levels in patients suffering
from auto-immune encephalitis (EAE), particularly MMP-2 and MMP-9 double
null mice resulted in inability to induce EAE (Agarwal et al., 2006). Due to
excessive degradation of ECM, MMPs also contribute to pathologies arising from
weakening of matrix such as abdominal aortic aneurysm (AAA) (Aziz and
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Kuivaniemi, 2007) and dialated cardiomyopathy, epidermolysis bullosa
(Thompson and Parks, 1996).

The requirement of proteolytic enzymes in invasive tumor growth
was recognized even before MMPs were discovered (Gersh and Catchpole, 1949).
The findings from studies conducted by Gersh and Catchpole showed that
fibroblasts secretions are important for tumor growth and invasion. Subsequently,
these secretions were characterized and identified as hyaluronidases, serine
proteases and MMPs.

The critical role of MMPs, specifically type-IV

collagenase, in tumor invasion and metastasis was first shown by Lance Liotta
(Liotta et al., 1980). The tissue breakdown and remodeling function of MMPs
helps in events such as tumor invasion, intravasation into circulation,
extravasation, and migration to metastatic sites and angiogenesis (Folgueras et al.,
2004; Deryugina et al., 2006). MMPs are over-expressed in a wide range of
malignancies with strong correlation between their over-expression and tumor
aggressiveness and prognosis (Egeblad and Werb, 2002). Studies underlining the
significance of MMPs in cancer are based on knock-out mouse models. MMP-7
null mice show reduced tumor formation (Wilson et al., 1997) while MMP-9
deficient mice showed decreased melanoma metastasis (Masson et al., 1998).
MMP-2 deficient mice show reduced melanoma tumor progression and
angiogenesis (Itoh et al., 1998).

Elevated levels of MMP-2 and MMP-9

contribute to accelerated tumor growth and progression in oral (Ikebe et al.,
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1999), lung (Kodate et al., 1997), bladder (Papathoma et al., 2000) and ovarian
cancer (Schmalfeldt et al., 2001). Increased levels of MT-MMP correlate with
tumor aggressiveness in laryngeal (Du et al., 1999) and esophageal cancer (Etoh
et al., 2000). Several studies show that insertion of a guanine (G) nucleotide at
position -1607 in the MMP-1 promoter creates a new ETS binding site thereby
increasing the transcription of the gene (Rutter et al., 1998). Presence of this 2G
nucleotide has been shown to increase the promoter activity of MMP-1 in GBM
(McCready et al., 2005) and invasion in colorectal cancer (Ghilardi et al., 2001)
and melanoma (Ye et al., 2001). Increased expreesion of MMP-2 and MMP-9 are
associated with low survival and increased aggressiveness in brain tumors
(Jaalijnoja et al., 2000; Choe et al., 2002).

The above findings emphasized a dire need to develop and test clinically
useful MMP antagonists. A large number of MMP inhibitors (MMPIs) are being
tested in various cancers in all the three phases of clinical trials (Sideras et al.,
2006; Robbins et al., 2008). The first of the MMPIs, Batimastat (BB-94) and
Marimastat (BB-2516) were pseudopeptide derivatives that mimic the structure of
collagen and blocked MMP activity by competing for the susbtrate-binding site.
However, BB-94 had low water-solubility and was not available orally. BB-2516
affected muculoskeletal systems due to off-target effects (Saghatelian et al.,
2004). Similar musculoskeletal toxicity has been observed in new MMPIs such
as prinomastat and BMS-275291 (Hidalgo et al., 2001; Miller et al., 2004). The
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clinical trial results have been found to be disappointing either due to side-effects
even at low dose of drugs or the drug was administered at an advanced stage of
cancer where MMP inhibition would no longer improve the survival (Robbins et
al., 2008).

1.7.4 Regulation of MMPs
To perform the functions during normal physiology and pathological
conditions, MMPs are tightly regulated at the transcriptional and translational
levels. In addition, the function of MMPs is regulated at protein levels by the
presence of endogenous inhibitors, the tissue inhibitors of metalloproteinases
(TIMPs).

Hormones, oncogenes, growth factors and cytokines influence the

transcription of most of MMP genes by interacting with AP-1 sites present in the
promoter region of MMP genes (Benbow and Brinckerhoff, 1997). Some MMPs
(MMP-1, -2, -3, -9 and -12) have single-nucleotide polymorphisms that generate
an extra ETS binding element site. This site acts synergistically to activate the
transcription of these genes (Rutter et al., 1998). Post-transcriptional regulation
includes stabilization of mRNA of MMP genes by phorbol esters, EGF and PDGF
(Vincenti et al., 2001). Most of the members of MMP family, collagenases,
gelatinases and stromelysins are secreted as zymogens. In the ECM, these
zymogens are cleaved by other proteases, such as plasmin or by other already
activated MMPs (Woessner and Nagase 2000). The TIMPs reversibly inhibit
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MMPs by binding in 1:1 stoichiometry (reviewed by Sternlicht and Werb 2001).
Other endogenous inhibitors of MMPs are α-macroglobulins that bind to MMPs
forming α-macroglobulins/MMP complexes that are cleared by scavenger
receptor-mediated endocytosis thereby inhibiting MMPs irreversibly (SottrupJensen and Birkedal-Hansen, 1989).

1.8 Matrix Metalloproteinase-1
Human fibroblast collagenase (MMP-1) was the first MMP to be
discovered (Gross and Lapiere, 1962), purified and cloned (Bauer, Eisen and
Jeffrey, 1970; Goldberg et al., 1986).

MMP-1 is also known as interstitial

collagenase, collagenase-1 or fibroblast collagenase with an official EC number
3.4.24.7. The human MMP-1 gene is located on chromosome 11q22.2-22.3 and
has 10 exons. It is tightly linked to a cluster of eight other MMPs including
MMP-3, -7, -8, -10, -12, -13 -20 and -27 (Puente et al., 2003). Human MMP-1 is
secreted as a proenzyme with 52 kDa as major form and 57kDa as minor
glycosylated form.

The cleavage of this pro-peptide yields an active and

functional MMP-1 with 42 kDa and 47 kDa in sizes respectively (Wilhelm et al.,
1986). Structurally, MMP-1 has minimal domain structure that has a hydrophobic
pre-domain directing it to endoplasmic reticulum (ER) for secretion. The propeptide has a cysteine residue at 73 position in a conserved region PRCGVPD
bound covalently through a-SH group to the zinc atom in the catalytic site. The
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enzyme becomes activated when this cyteine residue is displaced (cysteineswitch) by proteolytic cleavage or disruption by chemicals (Sprigman et al.,
1990). The catalytic domain contains a catalytic zinc bound in the sequence
HELGHXXGXXH by three His residues (Li et al., 1995). The crystal structure of
catalytic domain has five strands of β-sheet and three α-helices (Li et al., 1995).
The catalytic domain is connected by a linker region to a carboxy terminus
hemopexin domain. The hemopexin domain helps in enzyme substrate- binding
specificity for collagen and interaction with other proteins (Li et al., 1995).

The expression of MMP-1 is low during normal physiology but is elevated
when active tissue remodeling is needed. Various growth factors stimulate the
expression of MMP-1 by up-regulating signal transduction pathways that
converge to activate AP-1 (activator protein-1) transcription factors. Mitogen
activated protein kinase (MAPK) pathways activate ERK1/2, JNK and p38
protein to induce the expression of AP-1 proteins. These AP-1 proteins regulate
the expression of various genes involved in proliferation, development,
differentiation and tumor progression (Karin et al., 1997). The MMP-1 promoter
conatins a TATA box at approximately -30bp, and an AP-1 site at -72 with
respect to the transcription initiation site (Figure 1.6).
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Figure 1.6 Regulatory elements of MMP-1 promoter (Simplistic adaptation
from Ala-Raho and Kahari, 2005)
The figure shows important elements in the MMP-1 promoter that are discussed
in this work. Activator protein-1 (AP-1), nuclear factor κB (NF-κb), polyoma
virus enhancer activator-3 (PEA3), STAT binding element (SBE), TATA box
(TATA), TGF-β inhibitory element (TIE) are transcription factor binding sites.
An ETS site adjacent to AP-1 trancription factor binding site creates a ras
responsive element (RRE) at proximal promoter. In the presence of a single
nucleotide polymorphism (SNP) at -1607, another RRE is generated at the distal
promoter.

57

58

Another AP-1 site is present in the distal promoter at -186 position. The
Fos/Jun dimer binds to the AP-1 site which is adjacent to another cis-acting
sequence called PEA-3 (polyoma virus enhancer A binding protein 3) where
members of ETS transcription factor family bind (Karin et al., 1997; Sharrocks et
al., 1997). AP-1 and ETS transcription factors act synergistically to increase the
transcription of MMP-1 (Westermarck et al., 1997). As mentioned earlier, the
MMP-1 promoter exhibits single-nucleotide polymorphism (SNP). At position 1607, there is an extra guanine nucleotide generating ETS transcription factor
binding site. Together with an adjacent AP-1 site at -1602 position, it forms a ras
responsive element (RRE) (Rutter et al., 1998).

Oncostatin M enhances

expression of MMP-1 by activating STAT transcription factors that bind to SBE
and co-operate with AP-1 elements on MMP-1 promoter (Korzus et al., 1997)
(Figure 5). The p53 protein is a transcription factor that binds to a specific
consensus sequence in the promoter of several genes. In addition, it can also
interact with proteins to alter their functions. Although, MMP-1 promoter does
not have a p53 binding element, it has been shown that wild-type p53 downregulates MMP-1 transcription (Sun et al., 1999). Subsequently, it was shown
that down-regulation of MMP-1 by wild type p53 is due to its interaction with
p300 protein present in the transcriptional complex (Sun et al., 2004).

The

cytokine transforming growth factor-β (TGF- β) suppresses MMP-1 transcription
by binding to TGF- β inhibitory element (TIE) present on MMP-1 promoter at
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position -245.

Mutations in this element result in induction of MMP-1

transcription by tissue polypeptide antigen (TPA) (White et al., 2000).

The human MMP-1 mRNA has an AU-rich element which is important
for its stabilization (Vincenti et al., 1994). Activation of p38α results in MMP-1
mRNA stabilization (Reunanen et al., 2002) by activating a zinc-finger protein,
tristetraprolin that regulates the stability of AU-rich regions of mRNA (Carballo
et al., 2000).

Activation of latent precursor of MMP-1 by pro-domain proteolytic
cleavage takes place in a stepwise manner requiring interaction with plasminogen
activator urokinase and stromelysin (Suzuki et al., 1990). The serine proteases
cleave in the middle of pro-domain of MMP-1 generating a 46-kDa intermediate
form that is further cleaved between Val-67 and Met-68 residues forming a 43kDa
form. It needs to be cleaved further for a full activation and this requires cleavage
by MMP-3, -10 or MMP-7 between Gln-80 and Phe-81 (Ito et al., 1998; Suzuki et
al., 1990; Imai et al., 1995).

MMP-1 has been found to be over-expressed in normal physiological
processes like embryonic development and wound healing (McGowan et al.,
1994; Ravanti et al., 2000).

In addition, it is also found be elevated in

pathological states such as ulcers (Vaalamo et al., 1998) and a wide range of
60

cancers of breast (Wang et al., 1997), colon, stomach, ovary (Murray et al., 1996,
1998), pancreas (Ito et al., 1999) and skin (Nikkola et al., 2002). The presence of
SNP favors the growth and progression of ovarian and colorectal cancers
(Kanamori et al., 1999; Ghilardi et al., 2001). MMP-1 has also been found to be
over-expressed in brain neoplasms (Nakagawa et al., 1994; Nakano et al., 1995;
McCready et al., 2005).

1.9 Epidermal Growth Factor Receptor Signaling

For a cell to function normally, it requires nutrients and growth factors for
maintainance and proliferation. Growth factors communicate with the cell by
binding to transmembrane receptors presented on the surface of the cell. This type
of signaling is crucial to the development and survival of a normal cell during
typical physiological conditions.

In a cancer setting, such growth signaling

mechanisms go awry; the tight control on the activation and suppression of
signaling mediated by these growth factors becomes defective. The cells become
self-sufficient and constitutively produce these growth factors or they evade
mechanisms that inhibit the growth signaling (Hanahan and Weinberg, 2000).

Epidermal Growth Factor Receptor (EGFR) is an oncogene that is
involved in the regulation of several cellular processes mainly cell proliferation,
survival and migration. Altered regulation of EGFR activity is an important event
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that leads to formation and progression of various human malignancies in brain,
lung, breast, ovary, pancreas and prostate (Hynes and Stern 1994; Saloman DS et
al., 1995).

Structurally, EGFR is a 170kDa membrane spanning protein
consisting of 1186 amino acids. The receptor has an extracellular ligand binding
domain, a transmembrane domain and a cytoplasmic tyrosine kinase domain
(Ogiso H et al., 2002; Schlessinger J 2002).

The ErbB or Epidermal Growth Factor (EGF) family of receptor tyrosine
kinases (RTKs) include four members- EGFR/ErbB1/HER1, ErbB2/Neu/HER2,
ErbB3/HER3 and ErbB4/HER4. During normal physiological conditions, the
activation of EGFR is controlled by the expression and availability of its ligands,
EGF –related peptide growth factor family (reviewed by Riese and Stern 1998).
The ligands for these receptors have been divided into three groups- first group
includes EGF, Amphiregulin (AR) and transforming growth factor-α (TGF-α) that
bind specifically to the EGFR/ErbB1. The second group consists of heparinbinding EGF (HB-EGF) and epiregulin (EPR) that bind to both ErbB1 and ErbB4.
The third group has neuroregulins (NRG) that bind to ErbB4 (NRG-3 and -4) and
to both ErbB3 and ErbB4 (NRG-1 and -2). There is no direct ligand discovered,
so far, for ErbB2 suggesting that it is a co-receptor (Holbro T et al., 2003).
Among its ligands, EGF is an important regulatory factor that is present in
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abundance in various human cancers, either due to autocrine or paracrine
signaling pathways.

Binding of EGF to its receptor, EGFR, leads to receptor homo- or heterodimerization (Olayioye MA et al., 2000) followed by activation of the receptor‟s
tyrosine kinase domain through trans-tyrosine phosphorylation. The activated
receptor kinase phosphorylates the tyrosine residues on the C-terminal tail of the
ErbB receptors. These phosphorylated sites allow the binding of proteins with srchomology (SH2) domains such as Grb2, shc and Nck. These are adaptor proteins
that have intracellular docking sites for other proteins such as serine threonine
kinases that further activate other serine threonine kinases and transcription
factors (Olayioye MA et al., 2000). Thus, signaling from EGFR leads to an
amplification of several signaling pathways that alter protein function and gene
transcription favourable for oncogenesis. The best studied EGFR downstream
signaling pathways are RAS-RAF-MEK-ERK and PI3K-AKT pathways. During
normal conditions, the EGFR signaling is transient and is terminated either by
phophotyrosine phosphatases or after the receptor is endocytozed and binds to ccbl protein that targets it to degradatory pathways (Lipkowitz et al., 2003;
Muthuswamy et al., 1999).
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EGFR mediated signaling pathways

1.9.1 MAPK pathway.

Epidermal growth factor receptor stimulation leads to activation of several
signaling pathways including the mitogen activated protein kinase (MAPK)
pathway. The MAPKs are a large family of serine-threonine kinases that include
extracellular signal regulated kinases (ERKs), Stress activated protein kinases
(SAPK) or c-jun terminal kinases (JNKs) and p38 mitogen-activated protein
kinases. These kinases are phosphorylated and activated by MAPK kinases
(MKKs) which in turn are activated by MKK kinases (MKKKs) (Johnson GL et
al 2005). Upon EGF stimulation, the EGFR binds to adaptor proteins Grb2 or shc
and recruits son-of-sevenless (SOS) protein (Wu J et al 1993). The SOS protein at
the plasma membrane causes a small G protein RAS to release its GDP and
exchange it for GTP thereby activating it. The activated RAS targets its
downstream protein, Raf-1, which is a MKKK. Raf-1 kinase activates and
phosphorylates MKK, MEK1/2, that in turn activates ERK1/2. ERK1/2 is a
MAPK and it activates various other proteins such as ribosomal S6 protein kinase
(Rsk), MSK, cPLA2, c-Myc, Ets-2 and Elk leading to the increases gene
transcription of anti-apoptotic proteins (Bcl-2 and inhibitor of apoptosis, IAPs)
(reviewed in Henson and Gibson, 2006).
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1.9.2 PI3 kinase/AKT pathway. Phosphatidylinositol- 3 kinase
(PI3-kinase) protein has an SH2 domain that is needed for interaction with the
EGFR after its stimulation. PI3-kinase is recruited to the plasma membrane
where it catalyzes the transfer of a phosphate group from ATP to
phophatidylinositol generating a 3‟- phophatidylinositol phosphate (PIP3). This
process is reversed by phosphatase and tensin homolog protein (PTEN). PIP3
binds to proteins with pleckstrin homology (PH) domains. AKT (also called as
protein kinase B, PKB) is a serine-threonine kinase that has PH domain and binds
to PIP3 and gets phosphorylated. AKT has been regarded a key player in the
survival pathway of a cell by acting on its downstream targets that are categorized
into apoptotic proteins, transcription factors and protein kinases. AKT activates
transcription factors- NFκB, CREB and HIF-1α to increase the transcription of
anti-apoptotic proteins. AKT phosphorylates inhibitor of NFκB kinase (IKKα/β),
which phosphorylates and inactivates IκB. IκB dissociates itself from its NFκB
bound state and gets degraded releasing NFκB for nuclear translocation (Song et
al., 2005). EGFR inhibition sensitizes cells to apoptosis by de-activating AKT
(Longva et al., 2005). Glycogen synthase kinase- 3 is AKT downstream target
that gets inactivated by phosphorylation leading to reduced transcriptional activity
and metabolism (reviewed by Woodgett, 2005). AKT phosphorylates and
activates mTOR, mammalian target of rapamycin, a serine-threonine kinase.
mTOR activates ribosomal S6 kinase and eukaryotic initiation factor 4E- binding
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protein 1 (4E-BP1) leading to an overall increases survival and increased
translational activity in the cell (Sun et al., 2005).

Evidence of cross talk signaling between PI3K and MAPK has been
reported. Hyper-phosphorylated AKT also phosphorylates and inactivates Raf
thereby attenuating MAPK singaling (Zimmerman and Moelling, 1999).

In

addition, PI3K also activates RAS leading to the activation of MAPK pathway
(Jun et al., 1999).

1.10 EGFR biology in GBM
Published findings show that EGF stimulates tumor growth, invasion and
migration in an in-vitro glioma model (Lund-Johansen et al., 1990). EGFR overexpression is associated with resistance to radiation in malignant GBM cells
(Chakravarti et al., 2002) and poor response to radiation therapy in patients with
GBM (Barker et al., 2001). Radiation leads to EGFR activation and upregulation
of MAPK and PI3K pathways which then lead to an increased cytoprotective
response (Schmidt-Ullrich et al., 1997; Dent et al., 2003) and accelerated cell
proliferation (Carter et al., 1998).

Inhibition of EGFR radio-sensitizes and

induces apoptosis in malignant glioma (Birgit et al., 2008) leads to decreased
invasion, inhibition of U251 glioma cell growth (Stea et al., 2003) and
cytotoxicity in U87 glioma cell line (Yamoutpour et al., 2008). The interruption
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of MAPK and PI3K/Akt signaling pathways may provide mechanisms for
inhibition of tumor growth and overall survival.
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AIMS

The focus of this dissertation was to examine the function of MMP-1 in
GBMs.

Although, the primary substrate for MMP-1, collagen, is lacking in

GBMs, there is a significantly increased expression of MMP-1 in GBM as
compared to normal physiology. In recent years, mounting evidence shows that
MMPs do not just degrade ECM; they perform important functions by cleaving
bio-active molecules present in the ECM to activate various oncogenic signaling
pathways. Extensive literature suggests the involvement of MMP-1 in various
pathologies including cancer. Therefore, the regulation of this particular enzyme
is paramount for better therapy. In GBMs, a majority of patients have EGFR
signaling pathway abnormalities. We wanted to examine the correlation between
EGFR-mediated tumor aggressiveness and MMP-1 expression. Chapter 3 focuses
on the regulation of MMP-1 by EGFR and the signaling pathways associated with
it.
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CHAPTER 2

Matrix Metalloproteinase-1 over-expression in human
glioblastomas: Implications in glioma cell invasion
Anand M, Mullet E, McCready J, Abd-Elfattah N, Fuller CE, Broaddus WC, and
Fillmore HL
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2.1 Abstract
Glioblastoma Multiforme (GBM) is the most common form of primary
malignant brain tumor with a median survival of approximately one year postdiagnosis.

The highly invasive characteristic of GBM, an important factor

contributing to the failure of therapies, involves the action of proteolytic enzymes
such as matrix metalloproteinases (MMPs). MMP-1 is a key enzyme that leads to
invasion in many cancers by degrading extra-cellular matrix (ECM) proteins and
cleaving latent bioactive molecules that aid in the up-regulation of pro-invasive
proteins.

We examined the expression of MMP-1 in human GBM tissue

specimens and its function in GBM cell lines. The protein levels of MMP-1 in
GBM patient samples were analyzed using Enzyme-linked immunosorbent assay
(ELISA) and immunohistochemistry. Down-regulation of MMP-1 was performed
in T98G glioma cells by transient transfection with MMP-1 siRNA and MMP-1
over-expression was achieved in U251MG and U87MG cell lines by stable
transfection of a MMP-1-pIRES cDNA vector. Invasion and cell proliferation
assays were conducted. We observed that MMP-1 protein levels are elevated in
human GBM tissue as compared to normal brain.

Immunohistochemistry of

patient samples indicated that MMP-1 protein is present in both glioma cells and
endothelial cells.

Inhibition of MMP-1 expression in T98G cells by siRNA

resulted in a significant decrease in invasion compared to controls. Glioma cells
engineered to stably over-express MMP-1 showed a significant increase in
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invasion compared to controls. Thus, we can conclude that MMP-1 is overexpressed in human glioma tissue and can influence glioma cell invasion in vitro
suggesting its importance in glioma biology.

2.2 Introduction
Despite significant improvements in the diagnosis and treatment of
patients with glioblastoma multiforme (GBM), this primary brain tumor remains
essentially incurable. Initial treatment usually includes surgical resection of the
tumor mass, followed by radiation and chemotherapy. In virtually all cases the
tumor recurs, usually near the margins of the previous resection, often in a form
that is more resistant to subsequent therapies. A key feature that underlies the
malignant behavior of this disease is the ability of glioma cells to aggressively
infiltrate surrounding brain tissue (Zhu and Parada, 2002; Giese et al., 2003; Rao
et al., 2003). The presence of invasive cells in the brain surrounding the primary
tumor explains the tendency of these tumors to recur at these margins. Growth
factors, extracellular matrix molecules, and proteases are secreted from both
tumor and normal brain cells, and are likely to interact in complex ways to
contribute to the highly invasive behavior of GBM cells. Tumor cell invasion
involves interactions with and degradation of molecules of the extracellular
matrix followed by active cell migration. Matrix metalloproteinases (MMPs) are
important proteolytic enzymes that have been implicated in the invasion process
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in a wide variety of cancers (Egeblad and Werb, 2002). With over 25 members,
MMPs are classified as stromelysins (that cleave fibronectin and proteoglycans),
interstitial collagenases (that cleave triple helical regions of fibrillar collagens:
Types I, II, III, VII, VIII and X) and gelatinases (that cleave denatured collagen,
fibronectin, elastin and collagens: Types IV, V, VI, VII and X). MMPs are
tightly regulated at the transcriptional and translational levels and once secreted
from tumor or host cells, they can activate other proteases.

Accumulating evidence suggests

a correlation between elevated

expression of MMPs and glioma progression. Published findings show that MMP2 (Gondi et al., 2009; Kargiotis et al., 2008; Yamamoto et al., 1996; Lampert et
al., 1998; Vince et al., 1999), MMP-7 (Vince et al., 1999), MMP-9 (Ezhilarasan et
al., 2009; Lakka et al., 2005; 2002), MMP-14, MMP-15 (Fillmore et al., 2001)
and MMP-16 (Xia et al., 2009) are involved in brain tumor biology. Of the
matrix metalloproteinase family, MMP-2, MMP-14 and MMP-9 have been the
most extensively studied in brain tumors whereas MMP-1 has been less
characterized. Limiting the role of MMP-1 to collagen breakdown may have led
to a lack of study in the brain, where there are not significant quantities of
collagen type I. MMP-1, also known as collagenase I, was first described by
Jerome Gross in the early 1960s (Gross and Lapiere 1962; McCawley et al.,
2001). In addition to cleaving type I collagen, MMP-1 also activates MMP-2
(Vihinen et al., 2002) and stimulates MMP-9 release from cultured neural cells
72

and macrophages (Conant et al., 2002). Other than type I collagen, MMP-1 can
cleave aggrecan, laminin, tenascin and fibrin. It is also known to cleave latent
forms of cytokines such as pro-TNF- (McCawley et al., 2001).

We have

reported that there is a significant increase in MMP-1 mRNA levels in tumor
samples from patients with GBM relative to normal brain (McCready et al.,
2005). MMP-1, which is not typically expressed in normal brain (McCready et
al., 2005), has been shown to be elevated in glioma (Hodgson et al., 2009) and
correlates with tumor grade and survival time (Stojic et al., 2008; Nakano et al.,
1995). Herein we use an ELISA assay and immunohistochemical techniques to
examine the expression of MMP-1 protein in human glioma tissue. To investigate
the role of MMP-1 in glioma cell invasion, we have performed Matrigel-invasion
assays in glioma cell lines that were manipulated by stable over-expression and
transient siRNA-mediated inhibition of MMP-1. Results demonstrate that MMP1 expression promotes and MMP-1 suppression inhibits glioma cell invasion.

2.3 Materials and Methods

Cell Culture
Human GBM cell lines (T98G, U251MG and U87MG) were obtained
from American Type Culture Collection (ATCC, Manassas, VA, USA) and
maintained in Dulbecco‟s Modified Eagle Medium (DMEM Invitrogen, Carlsbad,
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CA, USA) supplemented with 4.5 g/l D-glucose, 1% penicillin/streptomycin
(Invitrogen) and 10% Fetal Bovine Serum (FBS) (Gemini Bio-Products, West
Sacramento, CA, USA). Cells were incubated in a humidified incubator at 37°C
with 5% CO2 in Nunclon 75cm2 culture flasks (Nunc, Germany) and harvested
with 0.25% Tryspin-EDTA (Invitrogen).

Tissue samples
Tumor tissue was obtained at the time of craniotomy and was dissected
free of adventitial material, snap-frozen in liquid nitrogen, and maintained in a
tissue bank at -800C, in accordance with a protocol approved by the VCU
Institutional Review Board. Confirmation of diagnosis of GBM was determined
by a staff neuropathologist.

Enzyme-linked immunosorbent assay
Total protein was extracted from 6 normal brain samples and 26 glioma
samples using Tissue Protein Extraction Reagent (T-PER, Pierce, IL) and
quantified using the Coomassie Plus Protein Assay Reagent Kit (Pierce, IL). 10μg
of total protein was subjected to a sandwich enzyme immunoassay. Capture and
detection antibodies were used (CLMABMMP1, ACL2MMP1, Cedar Lane,
Canada) and incubation was carried out at room temperature for 2 hours. After
the incubation, the plate was washed 5 times with PBS followed by addition of
tetramethylbenzidine. The plate was incubated in the dark at room temperature
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for 30 minutes, and the reaction was stopped by addition of 2.5N H2SO4. The
absorbance at 450 nm was measured by a microplate reader (Molecular Devices,
Inc., Sunnyvale CA).

Immunohistochemistry
The MMP-1 immunohistochemical (IHC) staining was performed using a
rabbit anti-MMP-1 antibody (Abcam catalog# ab38929, Cambridge MA) at a
dilution of 1:100. Slides were deparaffinized through 3 changes of Xylene for 5
minutes each and rehydrated through 2 changes of 100% reagent alcohol for 3
minutes each, 1 change of 95% reagent alcohol for 3 minutes, and 1 change of
80% reagent alcohol for 3 minutes. Endogenous peroxidase activity was blocked
by incubation in 0.3% hydrogen peroxide at room temperature for 5 minutes. The
IHC stain was performed using Heat Induced Epitope Retrieval (HIER),
consisting of a 20 minute incubation in Target Retrieval solution, pH 6 (Dako
Corporation, Carpinteria CA) and a 20 minute cooling period. Slides were placed
on an Autostainer PlusTM (Dako Corporation, Carpinteria CA), on which all
subsequent incubations were performed at room temperature and all washes
consisted of a rinse with Wash Buffer (Dako Corporation, Carpinteria CA).
Nonspecific binding sites were blocked with Serum Free Universal Protein Block
(Dako Corporation, Carpinteria CA) for 5 minutes. Slides were then washed and
incubated with the primary antibody at the above-mentioned dilution in Antibody
Diluent with Background Reducing Agents (Dako Corporation, Carpinteria CA)
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for 1 hour. An incubation with biotinylated goat anti-rabbit secondary antibody
(Vector Laboratories, Burlingame, CA), dilution 1:500 in previously noted
antibody diluent was followed by a wash, and subsequent incubation in
Envision+TM Dual Link (Dako Corporation, Carpinteria CA) for 30 minutes.
Slides were washed again and incubated for 10 minutes in DAB+
(diaminobenzidine--Dako Corporation, Carpinteria CA). Slides were removed
from the Autostainer PlusTM and counterstained with Gills III Hematoxylin (Poly
Scientific, Bay Shore, NY), blued in tap water, rinsed in deionized water,
dehydrated through 1 change of 80% reagent alcohol for 3 minutes, 1 change of
95% reagent alcohol for 3 minutes, and 3 changes of 100% reagent alcohol for 3
minutes each. The dehydration was followed with 3 clearing changes of Xylene
for 5 minutes each and coverslipped using Tissue Tek Glas Mounting Media
(Sakura, Torrance, CA) and 24x55 #1 coverglasses (Cardinal Health, McGaw
Park, IL).

Images were obtained using an Olympus DP72 digital camera

(Olympus America Inc, Center Valley, PA) mounted on a Nikon Eclipse E600
microscope (Nikon Instruments Inc, Melville, NY).

MMP-1 siRNA transient transfection
T98G cells were transfected with Silencer pre-designed siRNAs against
MMP-1: siRNA ID 1157 sense, GGUAUGAUGAAUAUAAACGtt (Ambion,
Austin, TX, USA), targeting between 1265 to 1285 bases in the human MMP-1
transcript. The cells were plated in complete media (without antibiotics) in six76

well plates at a density of 200,000 cells per well. At 80% confluence, media were
removed from the cells and the wells were washed with PBS followed by addition
of 800μl per well of Opti-MEM I reduced serum medium (Invitrogen).
Oligofectamine transfection reagent, Opti-MEM I and siRNA or scrambled RNA
(at concentrations of 30nM) mixtures were made and incubated at room
temperature for 20 min.

Then cells were treated with reaction mixtures of

scrambled siRNA and predesigned siRNA against MMP-1. The six well plates
were kept on a shaker at 37°C for 6 hours. Opti-MEM I supplemented with 30%
FBS was added (500 μl per well) for overnight incubation. Complete media were
added the next day (500μl per well). At the end of 48 hours, media were replaced
with serum-free media for overnight incubation at 37°C. Proteins were extracted
from conditioned media and cells after the overnight incubation.

Stable over-expression of MMP-1
U251MG cells were stably transfected with the pIRES-GFP-MMP-1
vector containing sequences for green fluorescent protein and MMP-1, as well as
G418 resistance. One million cells were transfected with 1μg DNA using the
Oligofectamine transfection method according to the manufacturer‟s protocol
(Invitrogen). Three days after transfection, medium containing 500μg per ml
Geneticin (G418, GIBCO) was added to the U251-vector control and MMP-1
over-expressing transfectants. The Geneticin–resistant cells were selected and
grown for further experiments. Afterwards, these cells were stably maintained in
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complete DMEM supplemented with 400μg per ml Geneticin. Over-expression
of MMP-1 was confirmed by immunoblot studies as shown in experimental
results below.

Immunoblot
Cell lysates and conditioned media were collected from the GBM cell
lines-T98G, U251MG and U87MG. In these experiments, the conditioned media
were collected and concentrated from a volume of 4ml to 250μl using Amicon
centrifugal filters (Millipore).

For preparation of cell lysates, the cells were

treated with ice cold RIPA buffer (150 mM NaCl, 50mM Tris, 1% NP-40, 0.5%
Sodium Deoxycholate, 0.1% SDS) supplemented with protease inhibitors
(Calbiochem).

The lysates were centrifuged at 14000 rpm for 20 min after

shearing with 26 gauge needles. Protein concentrations were determined using
DC Protein Assay (Bio-Rad, Hercules, CA, USA)

Expression of MMP-1 protein levels was determined by immunoblot
analysis. Proteins isolated from conditioned media (10ug) and cell lysates (30μg)
were separated in 4-12% polyacrylamide –bis-Tris gels (Invitrogen, Carlsbad,
USA) and transferred to a 0.45μm nitrocellulose membrane (Invitrogen, Carlsbad,
USA). After blocking in 5% milk in TBST (50mM Tris base, 150mM NaCl,
0.05% (v/v) Tween 20), the membranes were incubated with mouse monoclonal
anti-MMP-1 antibody (R & D Systems, Minneapolis, MN, USA at 1:200 dilution)
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in the blocking solution. Rabbit polyclonal anti-cyclophilin A antibody
(Millipore, Billerica, MA, USA) was used to quantify any variability in loading
onto the polyacrylamide gels. After washing the membranes in TBST, they were
incubated with horseradish peroxidase –conjugated secondary antibodies: goat
anti rabbit IgG and goat anti mouse IgG, (Rockland Immunochemicals,
Gilbertsville PA, USA) both diluted 1:5000 in 5% milk-TBST solution. Blots
were visualized with exposure of autoradiographic film using an enhanced
chemiluminescent system (ECL, GE Healthcare).

The developed films were

scanned and densitometry was performed using ImageJ.

Matrigel Invasion Assays
Invasiveness of GBM cell lines was determined using transwell inserts
(Corning Incorporated, USA) with 8μm pores. The inserts were coated with
growth factor reduced Matrigel (BD Biosciences, CA, USA) at a concentration of
100 μg per filter diluted in cold serum-free DMEM for 30 minutes at 37°C
incubator. 600 μl of 10% serum containing medium was added to the bottom
chamber. The cells at a density of 1x106 cells per ml were added to the top
chamber and incubated at 37°C for 48 hours. At the end of incubation, the cells
that passed through the Matrigel into the bottom chamber were counted under the
microscope from four random fields per transwell. Three replicates for each
experimental condition were analyzed.

79

Cell Proliferation Assays
Cell proliferation was measured using the CellTiter-Glo luminescent Cell
Viability ATP assay (Promega). 1000 cells per 100μL media were plated in 6
replicates per condition in white-walled 96 well plates (Corning Life Sciences).
At the end of each time point (days 0, 1, 3 and 5), 100 μl per well of Cell Glo
solution was added directly to the wells containing cells, with gentle shaking at
room temperature for 10 minutes followed by incubation at 4°C for 10 min. A
standard curve of known ATP concentrations was generated for each assay.
Luminescence was detected using a Fluostar Optima plate reader (BMG Labtech,
Durham, NC, USA), and ATP estimated based upon standard curve luminescence.
The measurement of number of cells was correlated with the luminescence
obtained from serial dilutions of cell-counts from each cell line.

Statistical Analysis
Data were evaluated by comparing the means and SEM of replicate
experiments.

Data are expressed as the mean and SEM of at least three

independent experiments.

Statistical analysis was done using an unpaired

Student's t test. P < 0.05 was considered significant.
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2.4 Results
Matrix metalloproteinase-1 is over-expressed in human
GBM tissue specimens
To determine the expression levels of MMP-1 in GBM, we analyzed
protein from 6 normal brain samples and 26 GBM patient samples. Of the 26
GBM samples tested, the majority of samples had MMP-1 levels ranging from 12
to 54 ng per 10 μg of total protein and only two had no detectable levels of MMP1. There were no detectable levels of MMP-1 in normal brain tissue samples
(Figure 2.1A). To confirm the expression and localization of MMP-1 in GBM
patients, we performed immunohistochemistry with paraffin-embedded sections
of

three

human

GBM

samples

using

an

antibody against

MMP-1.

Immunostaining confirmed the expression of MMP-1 in all of the GBM tissue
samples (Figure 2.1B), particularly in the perivascular regions of the tissues.
There was no detectable MMP-1 expression in normal brain adjacent to tumor
(Figure 2.1B).
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Figure 2.1 MMP-1 protein expression in GBM. A) MMP-1 protein levels
in normal versus GBM patient samples as measured by ELISA. B) MMP-1
expression in three representative GBM paraffin-embedded tissue samples.
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MMP-1 inhibition by siRNA leads to a decrease in glioma
cell invasion

MMP-1 has been established as an important contributor to invasion in
other malignancies. To examine if it has a pro-invasive function in glioma, we
first used siRNA to specifically inhibit MMP-1. The T98G cell line was used for
these inhibition studies due to the presence of a high basal level of MMP-1.
Treatment with 30nM MMP-1 siRNA inhibited the expression of MMP-1 in the
T98G cell line as observed in both conditioned media and cell lysates (Figure
2.2A).

Densitometric

analysis

demonstrates

a

decrease

in

MMP-1

immunoreactivity in both conditioned media (-76%) and cell lysates (-69%)
(Figure 2.2B). In a parallel experiment, invasive capacity of the T98G cells
treated with MMP-1 siRNA was examined. There was a significant decrease in
glioma invasion in cells that were treated with MMP-1 siRNA compared to
scrambled RNA-treated and no treatment controls (Figure 2.3C). To determine
whether the viability of cells treated with siRNA was affected, we performed
growth curves of control and siRNA-treated T98 cells using an ATP-based
viability assay (Figure 2.3D). There was no difference in ATP detection among
the various groups indicating that the siRNA does not affect the in vitro growth of
T98G cells.
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Figure 2.2 Transient inhibition of MMP-1 using siRNA leads to a
decrease in glioma invasion. A) Representative immunoblot of T98G cell lysates
(CL) and conditioned medium (CM) from cells treated with MMP-1 siRNA using
Oligofectamine at 30nM concentration in T98G cells, NT (no treatment), Scr
(scrambled control), Transfection reagent (Oligofectamine) and MMP-1 siRNA,
cyclophilin (cyc) is used as loading control for cell lysates. B) Densitometric
analysis of conditioned media and cell lysates (normalized to cyclophilin control)
from scrambled and siRNA treated samples. Data is representative of three
independent experiments and densitometric analysis is conducted across three
experiments (n=3). C) Matrigel- invasion assay shows the comparison of the
number of cells that invaded through a 100 μg matrigel (per filter) in a 48 hour
timeperiod between scrambled and MMP-1 siRNA treated T98G cells, * p value
< 0.005. D) Cell Proliferation Assay performed using Cell-Titer Promega kit in
T98G cells treated with scrambled (scr) and MMP-1 siRNA over 0, 1 and 3 days
time points show no difference in viability in MMP-1 siRNA treated T98G cells
compared to the scrambled treated control T98G cells. Data is mean of three
separate experiments (n=3).
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MMP-1 over-expression leads to increased invasion
Based on the results obtained from the inhibition studies we created
U251MG and U87MG cell lines that stably over-express MMP-1 (Figure 2.3A).
In normal culture conditions, these cell lines have low basal expression of MMP1. Following confirmation of over-expression of MMP-1 by immunoblots, the
parental, vector control and MMP-1 over-expressing cells were examined for
invasive potential in matrigel-based invasion assays. We found that MMP-1 overexpressing cell lines were significantly more invasive than the controls (Figure
2.3B).

There was approximately 50% increase in invasion in MMP-1 over-

expressing U87 cell lines over U87 vector control (p <0.05). In addition, U251
cells over- expressing MMP-1 were 68% more invasive than the vector controls
(p<0.05) (Figure 2.3B). To determine if the increased invasion was due to an
increase in cellular proliferation, we performed in-vitro cell proliferation assays
with the U251MG and U87MG stably transfected cells along with the controls.
We found that there was no observable difference in the proliferation rates among
the parental, vector controls and MMP-1 over-expressers (Figure 2.3C). These
results indicate that MMP-1 increases glioma cell invasion in vitro and suggest
that MMP-1 may play a role in GBM invasion.
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Figure 2.3 A). U251MG and U87MG cells were stably transfected with a
pIRES-GFP-MMP-1 cDNA vector with neomycin resistance. Immunoblots
confirm the over-expression of MMP-1 in conditioned media and cell lystaes
(cyclophilin used as loading control). B) Invasion assays using U251MG and
U87MG parentals (no treatment), vector control (pIRES-GFP with neomycin
resistance) and MMP-1 over-expression were performed. There is a significantly
increase in invasion in MMP-1 over-expressing U251MG and U87MG cells as
compared to the controls (vector control and parental). Data is representative of
three independent experiments, p*<0.05 (U251MG MMP-1 over-expressing cells
as compared to the vector-control), p#<0.05 (U87MG MMP-1 over-expressing
cells as compared to the vector-control) (n=3). C) Cellular proliferation assays
were performed using a Cell-Titer Promega kit. No difference was observed in the
cell proliferative ability among the three sample groups in each cell line. Data
shown is mean of three separate experiments, n=3.
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2.5 Discussion
In this study, we examined the role of MMP-1 in glioma cell invasion and
in-vitro cell proliferation. It is known that GBMs express MMP-1 (Hodgson et
al., 2009; Stojic et al., 2008; McCready et al., 2005; Nakano et al., 1995);
however, its specific role in high-grade glioma pathology is not yet determined.
Our results demonstrate that MMP-1 promotes the invasive potential of U251MG
and U87MG GBM cell lines, and inhibition of its expression in T98G reduces
glioma invasion. The ability to affect invasion is not due to a change in cellular in
vitro proliferation as this is not altered in cells with MMP-1 over-expression or
inhibition.

Invasion of brain tumor cells is one of the hallmark challenges that face
glioma-targeted therapies. During invasion, proteases released from both host and
tumor cells may interact with the extracellular matrix (ECM) molecules to
facilitate cell dispersal. Published findings report that gliomas express several
proteases including members of the matrix metalloproteinase (MMP) family
(Fillmore et al 2001; Bellail et al., 2004; Van Meter et al., 2001, Nuttall et al.,
2003). Matrix metalloproteinase-1 is an important contributor to invasion and
metastasis in a variety of cancers (Egeblad and Werb, 2002; Vihinen et al., 2002;
Ala-Aho and Kahari, 2005; Nikkola et al., 2005; Ghilardi et al., 2001;
Brinckerhoff et al., 2000; Wyatt et al., 2005; Behrens et al., 2001; Murray et al.,
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1996). Since there is a low abundance of type I collagen in the brain, the role of
MMP-1 in brain tumor invasion likely lies in a function distinct from its ability to
degrade collagen. In addition to its role of degrading collagen, MMP-1 can also
cleave latent precursors of bioactive molecules present in the ECM (Sternlicht and
Werb, 2001; Brinckerhoff and Matrisian, 2002).

These cleaved activated

molecules such as growth factors bind to their receptors leading to signaling
cascades that promote tumorigenesis including pro-invasive, proliferative, and
anti-apoptotic mechanisms. In this context, we speculate that MMP-1 mediates
brain tumor invasion largely by mechanisms other than by degradation of type I
collagen.

Recently, it has been shown that MMP-1 directly cleaves proteaseactivated receptor-1 (PAR-1), a G-protein coupled receptor (GPCR) and promotes
invasion in breast cancer (Boire et al., 2006) and melanoma (Blackburn et al.,
2009). PAR-1, also a pro-angiogenic receptor, has been proposed to be involved
in the invasion and metastasis of cancers of breast, ovarian, pancreas, prostate and
melanoma (Boire et al., 2006; Granovsky-Grisaru et al., 2006; Blackburn et al.,
2009; Agarwal et al., 2008; Salah et al., 2007) by triggering G-protein signaling
mechanisms in the cell that include increased calcium signaling, cell, migration,
gene transcription and mitosis. We speculate that such cleavage and activation of
PAR-1 by MMP-1 may form one of the mechanisms that lead to increased glioma
invasion. PAR-1 activation by MMP-1 not only stimulates pro-invasive GPCR
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signaling but also transactivates an important growth factor receptor, EGFR [4244]. In summary, MMP-1 may perform its pro-invasive functions dually by a)
indirectly up regulating pro-invasive factors in ECM and b) cleaving and
activating PAR-1 and downstream signaling.

Taken together, these findings suggest that inhibition or down-regulation
of MMP-1 may be beneficial in developing a more effective therapeutic approach
to improve the treatment of gliomas.
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CHAPTER 3

Epidermal Growth Factor induces metalloproteinase-1 (MMP1) expression and invasion in glioma cell lines via the MAPK
pathway.

Monika Anand, Timothy E Van Meter, and Helen L Fillmore
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3.1 Abstract
Glioblastoma Multiforme (GBM) is an aggressive cancer with a poor
survival rate. A key component that contributes to the poor prognosis is the
capacity of glioma cells to invade local brain tissue in a diffuse manner. Among
various proteases that aid in the process of invasion, matrix metalloproteinase-1
(MMP-1) has been identified as an important contributory factor in various
cancers. Apart from its traditional role in cleaving its primary extra-cellular
matrix (ECM) substrates, and like other members of the matrix metalloproteinase
family, MMP-1 can activate latent forms of bio-active molecules initiating
downstream pro-invasive and pro-oncogenic signaling mechanisms.

MMP-1

expression is regulated by several growth factors including epidermal growth
factor (EGF). Due to the fact that the epidermal growth factor receptor (EGFR) is
aberrantly overexpressed in GBM, we wanted to examine in greater detail the
signaling mechanisms by which MMP-1 expression and invasion is driven by
EGF in GBM cells. Treatment of T98G cells with EGF resulted in an induction
of MMP-1 expression following EGFR activation. Inhibition of EGFR by either
pharmacologic or genetic approaches abrogated this induction. Repression of the
mitogen activated protein kinase (MAPK) signaling led to the inhibition of EGFinduced MMP-1 whereas the PI3-kinase/AKT signaling was not associated with
EGFR-mediated MMP-1 induction. Inhibition of EGFR signaling also led to a
decrease in T98G invasion. These data suggests that EGFR mediated MMP-1

97

regulation is mainly via the MAPK pathway in T98G cells and inhibition of
EGFR and MMP-1 results in a decrease in T98G cell invasion.

3.2 Introduction

Glioblastoma Multiforme (GBM) is the most common and malignant
primary brain tumor (CBTRUS, Statistical Report, 2010). Despite multimodal
treatments involving surgical resection, chemotherapy and radiotherapy, the
survival rate is dismal, with a mean survival of approximately 11 months. One
major reason for the failure of therapies is the aggressive infiltration and invasive
nature of the tumor cells. Mechanisms of invasiveness are therefore important
parameters for studies in the identification of potential therapeutic targets for this
incurable cancer.

Growth factors, extracellular matrix molecules, and proteases are secreted
from both tumor and normal brain cells, and contribute to the highly invasive
behavior of GBM cells.

Tumor cell invasion involves interactions with and

degradation of molecules of the extracellular matrix (ECM) followed during
active cell migration.

Matrix metalloproteinases (MMPs) are important

proteolytic enzymes that have been implicated in the process of invasion in a wide
variety of cancers (Egeblad and Werb, 2002).
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Amplification, over-expression and mutations in EGFR gene are common
events (affecting ~ 65% of cases) in gliomas tumorigenesis, particularly in denovo GBM (Libermann et al., 1985; Wong et al., 1992; Frederick et al 2000).
EGFR is involved in the regulation of cell proliferation, motility and survival of
cells and an imbalance in the EGFR-ligand signaling axis can give rise to
neoplastic transformation via 1) increased production of EGFR ligands and
autocrine regulation, 2) increased expression of EGFR, 3) EGFR mutations that
lead to constitutive activation of the receptor, or 4) defects in the normal EGFR
down-regulatory processes (Zandi et al., 2007).

Mutations in the extra-cellular domain are particularly frequent in GBM,
especially the EGFRvIII mutation, also called as de2-7EGFR or δ2-7EGFR
(Zandi et al., 2007). EGFRvIII mutation results from an in-frame deletion of
exons 2 to 7 that encode subdomain I and 2/3rd of subdomain II (Wong et al.,
1992). The truncated receptor lacks the N-terminal ligand binding area, changing
the conformation of the receptor to allow autophosphorylation and constitutive
activation (Ekstrand et al., 1994). This activation is enough to induce and sustain
oncogenic signaling (Chu et al., 1997) but not sufficient to be recognized by its
degradatory proteins (Grandal et al., 2007). Stimulation of EGFR by its ligand
EGF leads to receptor homo- or heterodimerization (Olayioye et al., 2000)
followed by activation of tyrosine kinase domain of the receptor through transtyrosine phosphorylation.

The activated receptor kinase phosphorylates the
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tyrosine residues on the C-terminal tail of the ErbB receptors.

These

phosphorylated sites allow the binding of proteins with src-homology (SH2)
domains such as Grb2, shc and Nck that act like adaptor proteins that have
intracellular docking sites for other proteins such as serine threonine kinases.
This relays the signaling activating other serine threonine kinases and
transcription factors (Olayioye et al., 2000). Thus, signaling from EGFR leads to
an amplification of several signaling pathways that alter protein function and gene
transcription conducive for oncogenesis.

The best characterized EGFR

downstream signaling pathways are the RAS-RAF-MEK-ERK and PI3K-AKT
pathways.

Accumulating evidence suggests a correlation between elevated
expression of MMPs and glioma progression.

Published findings show that

MMP-1 (McCready et al., 2005; Stojic et al., 2008), MMP-2 (Gondi et al., 2009),
MMP-7 (Vince et al., 1999), MMP-9 (Ezhilarasan et al, 2009; Lakka et al., 2002),
MMP-14, MMP-15 (Fillmore et al., 2001; Zhang et al., 2005) and MMP-16 (Xia
et al., 2009) are involved in brain tumor biology. Of the matrix metalloproteinase
family, MMP-2, MMP-14 and MMP-9 have been the most extensively studied in
brain tumors whereas MMP-1 is less well-characterized. We have reported that
there is a significant increase in MMP-1 mRNA levels in tumor samples from
patients with GBM relative to normal brain (McCready et al., 2005). MMP-1,
which is not typically expressed in normal brain, has been shown to be elevated in
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gliomas (Hodgson et al., 2009) and correlates with tumor grade and survival time
(Stojic et al., 2008).

We wanted to examine if amplified EGFR signaling contributes to proinvasive MMP-1 protein up-regulation and determine if MMP-1 mediated activity
is an important contributor to GBM invasion. Herein, we report that MMP-1 is
regulated by EGFR. High expression of MMP-1 is observed after treatment with
EGF, and this is dependent on EGFR-driven downstream MAPK signaling.
Inhibition of EGFR using the pharmaceutical inhibitor, AG1478 led to the
suppression of the EGF induced MMP-1 protein levels. In addition adenoviral
mediated transfection of vectors that express dominant negative forms of MEK
and EGFR led to the inhibition of EGF induced MMP-1 while cells transfected
with adenoviral CA-MEK led to increased MMP-1. Functionally EGF induced
MMP-1 expression correlated with an increase in cellular invasion and treatment
with AG1478 abrogated this increase. Although not to the same extent, MMP-1
siRNA treated cells also blunted the EGF induced invasion.
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Data are expressed as the mean and SEM of at least three independent
experiments. Statistical analysis was done using an unpaired Student's t test. P <
0.05 was considered significant.

3.3 Materials and Methods

Cell Culture
Human GBM cell lines (T98G and U87MG) were obtained from American Type
Culture Collection (ATCC, Manassas, VA, USA) and maintained in Dulbecco‟s
Modified Eagle Medium (DMEM Invitrogen, Carlsbad, CA, USA) supplemented
with 4.5 g/l D-glucose, 1% penicillin/streptomycin (Invitrogen) and 10% Fetal
Bovine Serum (FBS) (Gemini Bio-Products, West Sacramento, CA, USA). Cells
were incubated in a humidified incubator at 37°C with 5% CO2 in Nunclon 75cm2
culture flasks (Nunc, Germany) and harvested with 0.25% Tryspin-EDTA
(Invitrogen). The cells were plated in six-well plates at the density of 200,000
cells/ml for 24h and then pre- treated with inhibitors AG1478 (300nM) and
PD184352 (500 nM) (Calbiochem, USA) for 1 hour before adding 20ng/ml EGF
(Cell signaling, USA).
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Immunoblot
Cell lysates and conditioned media were collected from the GBM cell linesT98G and U87MG. Prior to extraction of conditioned media and cell lysates,
complete serum media was aspirated from six-well plates well and washed with
PBS. One ml serum –free media was added to each well and incubated for 24h.
Then the conditioned media was aspirated and centrifuged at 1000 X g to remove
cell debris. The supernatant was collected and added to Amicon centrifugal filters
(Millipore) for concentration of the protein from 3ml to 250 μl. For preparation
of cell lysates, the cells were treated with ice cold RIPA buffer (150 mM NaCl,
50mM Tris, 1% NP-40, 0.5% Sodium Deoxycholate, 0.1% SDS) supplemented
with protease inhibitors (Calbiochem). The lysates were centrifuged at 14000
rpm for 20 min after shearing with 26 gauge needles. Protein concentrations were
determined using DC Protein Assay (Bio-Rad, Hercules, CA, USA)

MMP-1 protein level was determined by immunoblot analysis. Proteins isolated
from conditioned media (10ug) and cell lysates (30μg) were separated in 4-12%
polyacrylamide –bis-Tris gels (Invitrogen, Carlsbad, USA) and transferred to a
0.45μm nitrocellulose membrane (Invitrogen, Carlsbad, USA). After blocking in
5% milk in TBST (50mM Tris base, 150mM NaCl, 0.05% (v/v) Tween 20), the
membranes were incubated with mouse monoclonal anti-MMP-1 antibody (R &
D Systems, Minneapolis, MN, USA at 1:200 dilution) in the blocking solution.
Rabbit polyclonal anti-cyclophilin A antibody (Millipore, Billerica, MA, USA)
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was used to quantify any variability in loading onto the polyacrylamide gels.
After washing the membranes in TBST, they were incubated with horseradish
peroxidase –conjugated secondary antibodies: goat anti rabbit IgG and goat anti
mouse IgG, (Rockland Immunochemicals, Gilbertsville PA, USA) both diluted
1:5000 in 5% milk-TBST solution.

Blots were visualized with exposure of

autoradiographic film using an enhanced chemiluminescent system (ECL, GE
Healthcare). The developed films were scanned and densitometry was performed
using ImageJ.

Adenoviral Transfections
T98G cells were plated in six-well plates at a density of 200,000 cells per ml in
triplicates per condition. The adenovirus-pCMV, CA-AKT, DN-AKT, CA-MEK,
DN-MEK (Vector Biolabs, PA, USA) and DN-EGFR (Molecular Biology Core
Facility, VCU) were a kind gift from Dr Paul Dent, Virginia Commonwealth
University. The CA-AKT has myristoylation signal for membrane targeting and
increased activity. The DN-AKT has alanine residues substituted for threonine at
position 308 and serine at position 473. The CA-MEK has serine 221 alanine
mutation in MAPK kinase and DN-MEK has serine 217/221 glutamine mutation
in MAPK kinase. The DN-EGFR lacks 533 C-terminal amino acids as described
[21]. The cells were infected with these recombinant adenoviruses at an MOI of
25 for 48 hours. Then the media was aspirated and replaced with serum-free
media for overnight before immunoblotting.
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MMP-1 siRNA transient transfection
T98G cells were transfected with Silencer pre-designed siRNAs against MMP-1:
siRNA ID 1157 sense, GGUAUGAUGAAUAUAAACGtt (Ambion, Austin, TX,
USA), targeting between 1265 to 1285 bases in the human MMP-1 transcript.
The cells were plated in complete media (without antibiotics) in six-well plates at
a density of 200,000 cells per well. At 80% confluence, media were removed
from the cells and the wells were washed with PBS followed by addition of 800
μl per well of Opti-MEM I reduced serum medium (Invitrogen). Oligofectamine
transfection reagent, Opti-MEM I and siRNA or scrambled RNA (at
concentrations of 30nM) mixtures were made and incubated at room temperature
for 20 min. Then cells were treated with reaction mixtures of scrambled siRNA
and predesigned siRNA against MMP-1. The six well plates were kept on a
shaker at 37°C for 6 hours. Opti-MEM I supplemented with 30% FBS was added
(500 μl per well) for overnight incubation. Complete media were added the next
day (500μl per well). At the end of 48 hours, media were replaced with serumfree media for overnight incubation at 37°C.

Proteins were extracted from

conditioned media and cells after the overnight incubation.

Matrigel Invasion Assays
Invasiveness of GBM cell lines was determined using transwell inserts (Corning
Incorporated, USA) with 8μm pores. The inserts were coated with growth factor
reduced Matrigel (BD Biosciences, CA, USA) at a concentration of 100μg per
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filter diluted in cold serum-free DMEM for 30 minutes at 37°C incubator. 600 μl
of 10% serum containing medium was added to the bottom chamber. The cells at
a density of 1x106 cells per ml were added to the top chamber and incubated at
37°C for 48 hours. At the end of incubation, media from bottom chamber was
removed and trypsin-EDTA was added. The cells from bottom of the filter were
scraped and added to trypsinized cells. The cell number was assessed CellTiterGlo luminescent Cell Viability ATP assay (Promega). A standard curve of known
ATP concentrations was generated for each assay. The measurement of number
of cells was correlated with the luminescence obtained from serial dilutions of
cell-counts from T98G cell line.

Percent invasion was calculated as the

(luminescence values obtained from analyzing the cells that invaded the matrigel)
divided by the (luminescence obtained from cell-count added to the top well) X
100. Data from three separate experiments with five replicates for each condition
were analyzed.

Statistical Analysis
Data were evaluated by comparing the means and SEM of replicate experiments.
Data are expressed as the mean and SEM of at least three independent
experiments. Statistical analysis was done using an unpaired Student's t test. P <
0.05 was considered significant.
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Data are expressed as the mean and SEM of at least three independent
experiments. Statistical analysis was done using an unpaired Student's t test. P <
0.05 was considered significant.

3.4 Results
EGFR mediates regulation of MMP-1
T98G and U87MG glioma cell lines were examined for changes in the
expression of MMP-1 protein following EGF treatment. Addition of 20 ng/ml
EGF led to phosphorylation and activation of EGFR within 2 minutes and the
phosphorylation status was sustained over 15 min and 24 hour time points
(Figure 3.1A).

MMP-1 protein levels were analyzed in T98G and U87MG

glioma cell lysates and conditioned media 24 hours following EGF treatment.
MMP-1 levels were increased several fold in both cell lines (T98CL = 9 fold, p
<0.05 T98CM= 0.75 fold, p< 0.05 U87CL= 3 fold, p<0.05 U87CM= 6.5fold,
p<0.05) (Figure 3.1B, 1C). We next sought to inhibit the activation of EGFR
using the small molecule inhibitor, AG1478 in T98G cells. Addition of AG1478
(300 nM) 2h prior to treatment with EGF completely inhibited the activation of
EGFR by EGF (Figure 3.1D). MMP-1 protein levels were also decreased in
samples treated with AG1478 alone. These findings demonstrate that EGFR
activation by EGF specifically regulates the expression of MMP-1.
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Figure 3.1 Regulation of MMP-1 by EGF Representative immunoblots
of T98G and U87MG glioma cell lysates (CL) from A) cells treated with EGF (20
ng/ml) for 2, 10 and 15 min show activation of EGFR, B) cells treated with EGF
(20 ng/ml) for 24h demonstrate induction of MMP-1 in CL and conditioned media
(CM). C) Densitometric analysis of MMP-1 protein band intensity across three
independent experiments, p*<0.005 (n=3). D) Cells treated with AG1478
(300nM) for 24h show complete inhibition of EGFR activation and MMP-1
protein levels in T98G CL, Densitometric analysis across three independent
experiments, p*<0.05 (n=3).
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Involvement of MAPK pathway in the EGF mediated induction of
MMP-1

To determine downstream EGFR signaling pathways involved in the
increase in MMP-1 expression, T98G cells were first treated with selective
MEK1/2 inhibitors U0126 and PD184352. Pre-treatment with 500nM PD184352
for 2 hours before addition of EGF completely inhibited the phosphorylation of
ERK (Figure 3.2A, lanes 5 and 6).

EGF treatment had no effect on

phosphorylated or total ERK1/2 levels in this cell line (Figure 3.2A, lanes 2 and
4). MMP-1 levels were also examined in T98G cells treated with PD184352 for
24 hours. There was a suppression of MMP-1 induction in the presence of EGF
in the cells treated with PD184352 (Figure 3.2A lanes 5 and 6) suggesting
MMP-1 regulation is effected by the MAPK pathway.
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Figure 3.2 Inhibition of MAPK signaling by PD184352 and MMP-1 levels.
A) Representative immunoblot of T98G CL, from cells treated with PD184352
(500nM) for 24h indicating complete inhibition of ERK activation and decreased
induction of MMP-1 protein levels in the presence of EGF (CL, cell lysate; ERK,
p44/42 Erk1/2 Mitogen activated kinases). B) densitometric analysis of MMP-1 band
intensity across three separate experiments, p*,

**

<0.05 [*, DMSO (-EGF) Vs

PD184352 (-EGF)], [**, DMSO (+EGF) Vs PD184352 (+EGF)] (n=3).
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Involvement of MAPK pathway in the EGF mediated induction of
MMP-1

To examine more closely the possible involvement of the MAPK signaling
pathway in EGF-induction of MMP-1, we used adenoviral constructs targeting
MEK and EGFR. Constitutively active (CA) and dominant negative (DN)-MEK
and DN-EGFR –adenoviral constructs were transfected in T98G cells and levels
of phospho-ERK1/2- and total ERK1/2 and MMP-1 were examined (Figure 3.3).
The T98G cells transfected with DN-EGFR show decreased levels of p-ERK and
MMP-1 as compared to pCMV controls (Figure 3.3A lanes 1 and 4). In the
presence of DN-MEK, p-ERK and MMP-1 levels were reduced (Figure3. 3A
lane 3). Conversely CA-MEK increases MMP-1 protein amounts, with a slight
increase in the endogenous levels of p-ERK (Figure 3.3A, lanes 1 and 2). The
DN-MEK and DN-EGFR completely inhibit phosphorylation of ERK suggesting
MAPK as an integral component of EGFR downstream signaling.
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Figure 3.3 EGFR mediated MAPK signaling influences MMP-1 levels.
A) Representative immunoblot of T98G cells transfected with adenoviral vectors
CA-MEK, DN-MEK and DN-EGFR (MOI of 25) show complete inhibition of
ERK phosphorylation in cells treated with DN-MEK and DN-EGFR. MMP-1
levels are also decreased in these cell lines. B) Densitometric analysis across
three independent experiments showing fold change values of MMP-1 protein
levels relative to the pCMV control. The CA-MEK resulted in an approximately
3 fold increase in MMP-1 protein levels whereas transfection of DN-MEK
decreased MMP-1 levels to 0.3 fold and that of DN-EGFR decreased MMP-1
levels to 0.2 fold relative to the pCMV control (CA-Constitutive active, DNDominant negative). Data is representative of three separate experiments, p
***

<0.05 (n=3).
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Role of PI3-kinase pathway in EGF mediated MMP-1 regulation

We also wanted to examine the PI3 Kinase pathway and its potential influence on
EGF-induced MMP-1 expression.

T98G cells were pre treated with two

concentrations of AG1478 (10nM and 30nM) for 2 hours and stimulated with
EGF (20ng/ml). The activation status of EGFR, AKT and ERK was tested in
these treated samples. In the presence of EGF, p-EGFR was inhibited by AG1478
(Figure 3.4A lanes 1, 3 and 5). In agreement with Figure 2, EGF had no effect
on the p-ERK levels. There was a dose-dependent inhibition of EGF stimulated
p-Akt levels with increasing amounts of AG1478 (Figure 3.4A, lanes 1, 3, and
5). In addition, basal and EGF-stimulated p-ERK levels were unchanged and the
AG1478 treatment did not affect the phosphorylation status of ERK (Figure
3.4B). These observations suggest that in addition to the MAPK pathway, EGFinduction of MMP-1 may involve the PI3K pathway.
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Figure 3.4 AG1478 mediates its downstream effects via PI3-K
signaling

A) Representative immunoblot of T98G cells treated with two

different concentrations of AG1478 (10 and 30 nM) show decreased levels of pEGFR and p-AKT but no effect on p-ERK. B) Densitometric analysis of EGFR,
AKT and ERK (phospho- and total) immunoreactivity in the above immunoblots
across three separate experiments, p*<0.05
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Role of PI3-kinase pathway in EGF mediated MMP-1 regulation
To further examine the role of PI3K in EGF induced MMP-1 expression,
adenoviral constructs (CA-AKT and DN-AKT) were used to transfect T98G cells.
Successful adenoviral transfection was confirmed by immunoblotting to detect
phospho-Serine 473-AKT and total-AKT (Figure 3.5A).

Only the CA-AKT

treated T98G cells were shown to have high Serine-473 phosphorylation levels
(Figure 3.5A, lane 2). Surprisingly, the MMP-1 levels remain same in T98G
cells transfected with adenoviral- CA-AKT and DN-AKT plasmids and are
similar to the pCMV controls (Figure 3.5A, lanes 1 to 3). Consistent with earlier
data (Figure 3.3A lanes 1 and 4, 3.3B) T98 cells treated with adenoviral DNEGFR plasmids demonstrate a decrease in MMP-1 levels to 0.3 fold as compared
to the pCMVcontrol (Figure 3.5A, lanes 1 and 4, Figure 3.5B).
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Figure 3.5 PI3-K signaling does not influence MMP-1 levels

A)

Representative immunolot of T98G cells treated with adenoviral vectors CA-AKT
and DN-AKT (MOI of 25) show that CA-AKT led to phosphorylation of AKT at
473 position with no active AKT in the control samples. This increased
phosphorylation did not lead to alterations in MMP-1 levels. B) Densitometric
analysis of the MMP-1 immunoblots across three separate experiments showing
fold change values relative to the pCMV control. The DN-EGFR sample group
shows a decrease in MMP-1 levels to approx 0.3 fold as compared to the pCMV
control group. Data is representative of three independent experiments, p*<0.05,
n=3.
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EGF stimulates glioma cels invasion in vitro

We next wanted to examine whether MMP-1 upregulation by EGF is an important
event in the in vitro invasion process in glioma cells. T98G cells were treated
with DMSO and AG1478 in the presence and absence of EGF. Inhibition of
MMP-1 was performed using transient transfection of MMP-1 siRNA. Treatment
with AG1478 alone in T98G cells significantly decreased invasion as compared to
the DMSO control.

Similarly, MMP-1 siRNA treatment to T98G cells

significantly suppressed invasion as compared to the scrambled control (p < 0.05)
(Figure 3.6). The addition of EGF to T98G cells (No treatment, NT and DMSOtreated) led to an increase in invasion (p<0.05). The addition of EGF to AG1478
treated T98G cells did not increase invasion suggesting suppression of EGFRmediated pro-invasive signaling.

Interestingly, addition of EGF to MMP-1

siRNA treated T98G cells resulted in an increase in invasion but this increase was
not as pronounced as controls. This data suggests that MMP-1 inhibition results
in blunting the EGF-mediated increase in invasion and therefore contributes, in
part, to EGF-mediated invasion process.
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Figure 3.6 EGFR mediated increased invasion involves MMP-1 in
T98G cells. Representative immunoblot of T98G cells treated with controls (NT,
DMSO), AG1478, scrambled control, MMP-1 siRNA (with and without EGF)
show that MMP-1 levels are decreased in AG1478 and MMP-1 siRNA treated
cell lysates even in the presence of EGF. EGF stimulation induced MMP-1
protein levels in controls (NT, DMSO and scrambled). B) Addition of EGF to
T98G cells in controls (NT, DMSO and scrambled) led to a significant increase in
matrigel-invasion.

In the presence of AG1478, the EGF mediated increased

invasion is inhibited. MMP-1 siRNA treated T98G cells show decreased invasion
as compared to the controls. In MMP-1 siRNA treated T98G cells, an increase in
invasion was observed with addition of EGF. However, the induction of invasion
by EGF was suppressed in these MMP-1 siRNA treated cells as compared to the
induction of invasion in NT, DMSO and scrambled sample groups. Data is
representative of three independent experiments, p*<0.05, p#(Scrambled Vs
MMP-1 siRNA) <0.05, p**(AG1478 Vs DMSO, No EGF) <0.05, p##(AG1478 Vs
DMSO, with EGF) <0.05 (n=3).
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3.5 Discussion

EGFR expression and mutation is an important hallmark event in many cancers,
including glioblastoma (GBM). Particularly, primary GBMs, also known as denovo GBM have been found to have a higher EGFR mutation rate than
progressive or secondary GBM (Ohgaki and Kleihues, 2007), and is recognized to
be a significant oncogene driving the growth and malignancy these cancers.
There is evidence for the involvement of MMP-1 in local diffuse invasion in
GBM (Stojic et al., 2008; McCready et al., 2005; Anand M et al, submitted).

In this study, we sought to examine the role of EGFR signaling in the EGF
induction of MMP-1.

We observed that by perturbing EGFR using EGF

stimulation in 2 glioma cell lines, MMP-1 expression was increased. In the same
model system, inhibition by AG1478 and EGFR- dominant negative forms, levels
of MMP-1 are altered. Subsequently, we explored EGFR downstream MAPK
and PI3-K signaling mechanisms.

Using a pharmaceutical inhibitor for the

MAPK pathway, PD184352, we observed an abrogation in the induction of
MMP-1 protein levels in samples treated with the inhibitor and EGF. Neither the
addition of EGF nor adenoviral mediated-infection of MEK-CA in T98G cells
increased the phosphorylation of ERK above the basal levels of p-ERK.
However, the transfection of Ad-EGFR-DN in T98G cells led to the suppression
of phosphorylated ERK and abrogated MMP-1 levels suggesting EGFR-mediated
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MAPK regulation of MMP-1.

In T98G cells infected with an adenoviral-

construct MEK-DN, MMP-1 levels were abolished. In addition, infection of
T98G cells with adenoviral-MEK-CA led to a robust increase in the MMP-1
protein levels strongly suggesting involvement of MAPK pathway in MMP-1
gene regulation.

AG1478 treatment led to the suppression of p-EGFR and p-AKT levels
but did not alter p-ERK levels. It also resulted in decreased MMP-1 levels
suggesting that PI3K signaling might also be involved in the EGF-MMP-1
regulation. There was an apparent dose-dependent decrease in phosphorlyated
EGFR with AG1478 treatment.

In figure 3.4 we show that with two doses of

AG1478 (10 and 30nM) there is a modest dose dependent decrease in
phosphorylated EGFR. The addition of higher doses of AG1478 (100 and 300
nM) completely inhibited phosphorylation of EGFR (data not shown).

We further explored the PI3-K signaling pathway by infecting T98G cells
with Ad-AKT-CA and Ad-AKT-DN. Interestingly, neither Ad-AKT-CA nor AdAKT-DN transfection in T98G cells altered MMP-1 levels suggesting that PI3K
may not involved in the EGF-induction of MMP-1 protein.

MMP-1 has pro-invasive functions in wide range of malignancies. In
order to examine, if EGFR mediated increase in MMP-1 plays a functional role in
130

T98 cells, we performed invasion assays. There was a significant increase in
invasion with EGF treatment and with AG1478 treatment this EGF-driven
invasion nis abolished. The MMP-1 siRNA demonstrated a similar effect. When
EGF was added to the MMP-1 siRNA treated cells, although not to the same
extent as with AG1478, there was a suppression of the EGF-driven invasion.
Thus, MMP-1 inhibition is able to blunt the EGF-mediated increase in invasion in
T98G cells emphasizing an important contribution to glioma cell in vitro invasion
by MMP-1.
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CHAPTER-4

GENERAL DISCUSSION
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In this study, we have shown that MMP-1 is a significant contributor of glioma
invasion in vitro.

Preliminary studies from our laboratory by Dr Jessica

McCready showed that MMP-1 mRNA is not detectable in normal brain but its
expression is increased in GBM tissue specimens. The MMP-1 protein levels in
GBM tissue specimens were examined using immunohistochemistry and
confirmed these earlier results. T98G cell lines were used for transient inhibition
of MMP-1 as they have high basal expression of MMP-1.

Conversely, the

U251MG and U87MG cell lines have low basal expression of MMP-1 making
them a suitable model for over-expression studies. Inhibition of MMP-1 using
siRNA in T98G cell lines showed a decreased invasion while stable overexpression of MMP-1 in U251MG and U87MG GBM cell lines exhibited
significantly increased invasion. These MMP-1 over-expressers have the ability
to invade growth factor- reduced matrigel barrier (at 100 μg/ filter concentration)
within 12 hours as observed under the microscope.

Several MMPs have been implicated in brain tumors; among them, the
most extensively studied are MMP-2 and MMP-9 (Kargiotis et al., 2008; Gondi et
al., 2009; Ezhilarasan et al., 2009; Lakka et al., 2002, 2005).

The studies

presented in this dissertation focused on the functional role of MMP-1 in GBM,
particularly invasion. MMP-1 contributes to invasion and metastasis in various
malignancies including breast, colon, ovary, skin and pancreas (Murray et al.,
1996; Kanamori et al., 1999; Ito et al., 1999; Brinckerhoff et al., 2000; Behrens et
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al., 2001; Ghilardi et al., 2001; Wyatt et al., 2005; Nikkola et al., 2005; Ala-aho et
al., 2005). In most of these cancers, MMP-1 favors tumor progression, growth
and invasion by its traditional function of degradation of rigid constituents of
ECM. However, brain ECM is devoid of such rigid barriers and it composed of
loosely bound hyaluronan, proteoglycans, tenascin-C and thrombospondin.
Nonetheless, collagen types IV, V, fibronectin and laminin are present in low
amounts along the vessel walls alongside basement membrane and peri-vascular
matrix (Bellon et al., 1985). Brain tumors rarely metastasize outside the brain and
there is no intravasation in GBM (Bellail et al., 2004). The GBM cells show a
pattern of infiltration along the periphery of vessel walls and white matter along
with widespread movement within the brain. It is important to note here that
despite the presence of very low quantities of known MMP-1 substrates around
peri-vascular region, over-expression of MMP-1 increases invasion significantly.
It is therefore possible that the increased invasion mediated by over-expression of
MMP-1 is not solely due to degradation of ECM. The above findings compelled
us to consider additional functions of MMP-1 in ECM dynamics.

MMP-1 alters invasion in GBM by cleaving biologically active molecules
We considered two substrates of MMP-1 that have been shown to be activated:
IGFBP2/3 and PAR-1. MMPs function in conjunction with each other and nontraditional substrates for MMPs are continuously being identified.

MMP-1

cleaves various bio-active molecules present in the ECM to up-regulate oncogenic
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signaling (Sternlicht and Werb, 2001; Brinckerhoff et al., 2002).

Literature

review lends evidence that insulin-growth factor binding proteins (IGFBPs)
present in ECM are cleaved by MMP-1 and MMP-3 (Fowlkes et al., 1994; Rajah
et al., 1999). IGFBPs are highly over-expressed and correlate with increased
invasion in GBM (Zhang et al., 2002). Silencing of IGFBP-2 in human GBM
cells reduced invasion (Fukushima et al., 2007) and its over-expression promotes
glioma development and progression (Dunlap et al., 2007).

Because of this

correlation between MMPs and IGFBPs, we examined the affect of active and
functional MMP-1 on IGFBPs (Appendix E). In summary, our preliminary in
vitro data suggests that MMP-1 does not cleave IGFBPs in T98G cells.

Recent studies have shown that MMP-1 directly cleaves a G-protein
coupled receptor (GPCR), Protease-activated Receptor (PAR-1), which is also a
pro-angiogenic molecule (Boire et al., 2006; Blackburn et al., 2009). Cleavage of
PAR-1 leads to activation of downstream G-protein couple signaling that aids in
the invasion, metastasis, growth, proliferation and aggressiveness of several
malignancies (Granovsky-Grisaru et al., 2006; Salah et al, 2007; Agarwal et al
2008). PAR-1 is expressed extensively in human brain on neurons and astrocytes.
Activation of PAR-1 in both astrocytes and human GBM cell lines (U178)
increases the intracellular calcium ion concentration suggesting it is equally
functionally active in normal and pathological states of brain (Junge et al., 2004).
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We tested the presence of PAR-1 in T98G, U251MG and U87MG GBM
cell lines via western blot analaysis but were unable to detect PAR-1. This could
be due to the low or nil expression of PAR-1 in in vitro conditions in these cell
lines and a more sensitive method such as ELISA is needed to detect the receptor.
It would be interesting to examine the PAR-1 cleavage and activation of
downstream GPCR signaling in the U251MG cells stably over-expressing MMP1. The high levels of MMP-1 protein expressed by U251-MMP-1OE clones
should be activated to achieve a functional and active form of MMP-1. This can
be obtained by treating the conditioned media from these cells with APMA
followed by dialysis for removal of the organo-mercurial compound.

The

resulting conditioned media can be used to treat the cells for examining the PAR1 cleavage. The PAR- cleavage can be determined by measuring the PAR-1
cleaved fragment using ELISA and intracellular concentration of calcium ions.

The in-vitro invasion assays performed with MMP-1 over-expressing
U251MG and U87MG cell lines showed an increase in invasion without altering
the cell-proliferation rate. In the same lines, siRNA inhibition of MMP-1 in
T98G cell lines showed a decreased invasion without affecting the cell viability
and proliferation rate as measured by cell proliferation assays. Thus, MMP-1 may
affect on the cell morphology which changes during the physical movement of the
cell. In experiments where recombinant active MMP-1 was added to the cells
during the invasion assay, we observe no difference in invasion as compared to
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the controls. Based on these findings, one would also believe that MMP-1 is not
affecting the growth or proliferation of the cells in-vitro. However, in a parallel
in-vivo study performed by my colleague, Dr Nicholas A Pullen, we observed that
these MMP-1 over-expressing U251MG cell lines show significant increase in
tumor growth and volume.

Moreover, the T98G GBM cell lines stably

transfected with lentiviral MMP-1 shRNA show a stark decrease in tumor volume
(Pullen et al., 2010–submitted). These results emphasize the importance of the
tumor microenvironment and its role in mediating the effects of MMP-1.

A majority of GBM patients have amplification, over-expression and/ or
mutation in the EGFR making this particular receptor an attractive target for
therapeutics.

EGFR is known to up-regulate various oncogenes that are

implicated in cell proliferation, invasion, metastasis and tumor growth.

In this study we demonstrated the induction of MMP-1 by EGF. EGF, at
concentration of 20ng/ml for 24h show an induction of MMP-1 in T98G and
U87MG cell lines. Using a pharmaceutic inhibitor of EGFR, AG1478 at a dose of
300 nM, we observed a complete inhibition of EGFR activation.

After the

treatment with AG1478 (300 nM) in T98G cell lines for 24 hour time period, we
observed that MMP-1 levels are completely abolished in the AG1478 treated
samples as compared to the controls. This data confirms that EGFR is playing an
important role in the regulation of MMP-1 expression.
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To understand the downstream signaling mechanisms that are mediating
the EGF-MMP-1 regulation, we used pharmaceutic inhibitors to two of the most
important and extensively studied pathways- MAPK and PI3-K/AKT.

For

MAPK inhibition, we used the U0126 inhibitor at a dose of 30 μM. Inhibition of
PI3K-AKT pathway was performed using LY294002 (5 μM). We observed that
with U0126, phosphorylation of ERK (p-ERK) is inhibited and over a 24 hour
time period, the MMP-1 levels are also abrogated. These experiments were
performed in the presence and absence of EGF (20 ng/ml). We also notice that
addition of EGF did not increase p-ERK levels above the existing high basal
levels. Treatment of T98G cells with LY294002 did not prove to be conclusive
because the cells did not survive at the period of 24 h.

A dose dependent

inhibition experiment was performed using the drug that shows complete
inhibition of p-AKT starting at 5 μM and almost complete inhibition at 10 μM.
Nonetheless, the cells did not tolerate lower doses of the drug over a 24 h time
period. To perform MAPK inhibition at a more physiologically relevant dose, we
also used another inhibitor, PD184352 at 500 nM.

This inhibitor treatment

resulted in same results as U0126 lending credence to the involvement of MAPK
in MMP-1 regulation.

An important observation was made in T98G cells treated with both
agonist (EGF) and antagonist (AG1478) of EGFR. In these cells, EGF led to an
activation of EGFR and AKT.

Inhibition of EGFR receptor activation also
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resulted in decreased p-AKT levels. However, the levels of p-ERK were entirely
unaffected with EGF and AG1478. At a 10 nM dose of AG1478, the extent of
inhibition on AKT is more pronounced than on its primary target, EGFR. This
may suggest that AKT pathway could be very sensitive to inhibition of EGFR; a
small inhibition in the receptor results in a marked decrease in the activation of
AKT.

A more specific approach to inhibit the signaling pathways was adopted
using adenoviral vectors that target the effector proteins of the pathways. These
adenoviral vectors were a kind gift from Dr Paul Dent laboratory, Department of
Biochemistry, Virginia Commonwealth University. The recombinant adenoviral
vectors were EGFR-dominant negative (DN), AKT-constitutive active (CA),
AKT-DN, MEK-CA and MEK-DN. We observed that infection with Ad-EGFRDN decreased the MMP-1 protein levels substantiating our earlier results with the
pharmaceutic inhibitor, AG1478. Ad-MEK-DN remarkably decreased the MMP1 levels and also inhibited the activation of ERK. Surprisingly, Ad-EGFR-DN
also resulted in the inhibition of ERK activation suggesting MAPK is indeed
downstream to EGFR signaling.

Ad-AKT-CA infection show increased

phosphorylation and activation of AKT at position serine -473. However, there
was no change in the levels of MMP-1 with Ad-AKT-CA and Ad-AKT-DN. This
data strongly highlights the involvement of MAPK pathway in EGFR mediated
regulation of MMP-1.
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The fact that we could not detect a change in p-ERK levels following
addition of EGF could be due to high basal p-ERK expression in T98 cells. . The
increase in p-ERK levels with EGF may not be detectable over this high-basal
level.

With addition of adenoviral dominant negative-EGFR, we observe

complete inhibition of the ERK phosphorylation, however this inhibition was not
observed with AG1478, a pharmaceutic inhibitor.

AG1478 is a reversible

inhibitor that binds to the ATP-binding pocket of the activated receptor. Our
earlier results with AG1478 pointed to inhibition of AKT at much lower doses
than it inhibits its specific receptor, EGFR. This suggests that AKT pathway is
more sensitive to AG1478 treatment whereas inhibition of MAPK pathway
requires more permanent and robust approach, more so, as the basal levels of
pERK are high.

We found that in Ad-MEK-CA transfections, there is a slight increase in
the phosphorylation of ERK. We had expected a more robust increase of pERK
due to the large increase in MMP-1 exprssion. There is a possibility of cross-talk
mechanisms between MEK1/2 and JNK. Published findings hint that ERK may
not the only target for MEK1/2 (Adler et al., 2005). In U251 GBM cell lines,
hyperphosphorylated MEK1/2 can phosphorylate JNK which further activates p38
MAPKs (Adler et al., 2005).

These proteins increase the pool of AP-1

transcription factors in the cell and can lead to increases in MMP-1 transcription.
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We also explored the role of another important signaling pathway
downstream to EGFR in the regulation of MMP-1- the JAK/STAT pathway. In
T24 bladder cancer cells, STAT3 activation was found to be important and
necessary for MMP-1 induction by EGFR (Itoh et al., 2006). We wanted to
determine if such a mechanism may also be part of GBM cells. To investigate the
role of JAK/STAT pathway, we used siRNA against STAT3 in T98G cell lines
and examined MMP-1 levels (Appendix F).

We had expected that STAT3 siRNA would decrease the levels of MMP1. But, we observed completely contrary to what we had anticipated. The
STAT3 siRNA treated T98G cells show an induction of MMP-1 as compared to
the scrambled and transfection regeant control. To determine if other signaling
pathways become activated in the event of STAT3 depletion as a compensatory
mechanism, we examined the MAPK pathway activation by analyzing p-ERK
levels. We observed that pERK levels did not change in the STAT3 siRNA T98G
cell lines. In the absence of any stimulatory signal (such as EGF), we could not
detect and discern any differences in pAKT levels, although the total AKT levels
remain constant.

Recent studies show that STAT3 has a tumor suppressive

function in the GBM cells. Interleukin-8 (IL-8) is a direct repressed target gene
for STAT3 (de la Iglesia et al., 2008). This repression is released during siRNA
inhibition of STAT3 thereby allowing IL-8 to mediate its downstream signaling
that may up-regulate MMP-1 expression.
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We have seen that in GBM cell lines, EGFR is regulating MMP-1
expression preferentially by the MAPK pathway. We next sought to determine if
EGFR mediated increased MMP-1 has a functional role of invasion. The T98G
cells were treated with controls, AG1478 and MMP-1 siRNA and allowed to
invade in a matrigel-based invasion assay in the presence and absence of EGF.
We show here that MMP-1 siRNA significantly decreased invasion as compared
to the controls corroborating our earlier data. In controls, the EGF treatment led
to a significantly increased invasion but in the presence of AG1478, the cells
drastically reduced this EGF-mediated increased invasion. Addition of EGF to
MMP-1 siRNA treated T98G cells resulted in a blunting of the EGF-driven
increase in glioma invasion. MMPs are regarded as main players in the invasion
process and as such other MMPs may be regulated by EGF and EGFR. Previous
published reports by our laboratory (Van Meter et al., 2004) report the induction
of MT1-MMP by EGF stimulation.

In summary, we have shown that MMP-1 plays a role in GBM invasion in
vitro. The increased expression of MMP-1 could be attributed to the complex
milieu of tumor microenvironment that is teeming with growth factors and
oncogenic stimuli. In our studies, we found that EGFR is regulating MMP-1
expression by MAPK pathway in T98G GBM cell lines. The finding by others
that MMP-1 can cleave PAR-1 is an important development in MMP-1 biology.
One proposed hypothesis is that once activated MMP-1 cleaves PAR-1, not only
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the GPCR, but other RTKs get activated by transactivation mechanisms. There
are unpublished reports that hint that EGFR can be shed by MMPs (personal
communication). The activation of EGFR and GPCR signaling pathways upregulate various oncogenic and invasive genes including MMP-1 thereby creating
a feedback loop (Figure 4.1). With the aid of tumor micro-environment, cancer
cells must maintain such feedlack loop constitutively for survival and growth.
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Figure 4.1
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Appendix A:
Cloning strategy for MMP-1
MMP-1 was purchased in the pOTB7 vector that had been modified with attB sites. This
would allow cloning into an entry vector (pDONR221) using the Gateway system by
Invitrogen. Once the entry clone is obtained, MMP-1 can be moved into a variety of
destination vectors using the Invitrogen Gateway cloning system. The pIRES2Ac-GFP, a
vector from Clontech, has been converted to a destination vector and was used for this
project.

MMP-1/pOTB7 and pDONR221 DNA (1:1 molar ratio) was set up in a BP reaction and
1ul was transformed into electrocompetent α–select cells from Bioline. The BP reaction
is mediated by BP clonase enzymes composed of Integrase and Integrase host factor
(IHF) proteins that facilitate the recombination between DNA clones containing attB sites
and a donor vector with attP sites. The cells were plated on kanamycin plates (50ug/ml
LB agar).

Colonies were analyzed by the Epicenter Colony Fast-Screen Kit

(Cat#FS0472H). The correct colony was struck on another kanamycin LB (Luria Broth)
agar plate and a single colony was used for inoculation of a miniprep culture. DNA was
isolated using the Fermentas GeneJet Miniprep Kit (Cat#K0503).

The DNA was

digested with NsiI enzyme that would disrupt the kanamycin gene of the pDONR221
backbone. The DNA was purified using the PCR cleanup procedure of the Promega
Wizard SV Gel and PCR Cleanup System (Cat#A9282)
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MMP-1/pDONR221 DNA and pIRES2Ac-GFP/rfa DNA (1:1 molar ratio)
was set up in an LR reaction and 1µl was transformed into electrocompetent α–
select cells from Bioline. In an LR reaction, the integrase, IHF and excisionase
(Xis) enzymes catalyze the recombination between entry clone (carrying gene of
interest flanked with attL sites) and a destination vector with attR sites. The cells
were plated on kanamycin plates (50ug/ml LB agar). Colonies were analyzed by
the Epicenter Colony Fast-Screen Kit (Cat#FS0472H). The correct colony was
struck on another kanamycin LB agar plate and a single colony was used for
inoculation of a day culture. An overnight maxiprep culture was inoculated from
the day culture.

DNA was isolated using the Invitrogen PureLink HiPure

Maxiprep Kit (Cat# K210007).
BP Reaction Creating a Gateway® entry clone from an attB-flanked PCR
product Add the following components to a 1.5 ml tube at room temperature and
mix: attB-PCR product (=10 ng/µl; final amount ~15-150 ng) 1-7 µl Donor vector
(150 ng/µl) 1 µl TE buffer, pH 8.0 to 8 µl
1. Thaw on ice the BP Clonase™ II enzyme mix for about 2 minutes. Vortex
the BP Clonase™ II enzyme mix briefly twice (2 seconds each time).
2. To each sample (Step 1, above), add 2 µl of BP Clonase™ II enzyme mix
to the reaction and mix well by vortexing briefly twice. Microcentrifuge
briefly.
3. Return BP Clonase™ II enzyme mix to -20°C or -80°C storage.
4. Incubate reactions at 25°C for 1 hour.
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5. Add 1 µl of the Proteinase K solution to each sample to terminate the
reaction. Vortex briefly. Incubate samples at 37°C for 10 minutes.

LR Reaction Transferring the gene from a Gateway® entry clone to
destination vector

1. Add the following components to a 1.5 ml tube at room temperature and mix:
Entry clone (50-150 ng) 1-7 µl
2. Destination vector (150 ng/µl) 1 µl, TE buffer, pH 8.0 to 8 µl
3. Thaw on ice the LR Clonase ™ II enzyme mix for about 2 minutes. Vortex the
LR Clonase ™ II enzyme mix briefly twice (2 seconds each time).
4. To each sample (Step 1, above), add 2 µl of LR Clonase ™II enzyme mix to the
reaction and mix well by vortexing briefly twice. Microcentrifuge briefly.
5. Return LR Clonase ™ II enzyme mix to -20°C or -80°C storage.
6. Incubate reactions at 25°C for 1 hour.
7. Add 1 µl of the Proteinase K solution to each sample to terminate the reaction.
Vortex briefly. Incubate samples at 37°C for 10 minutes.

Cloning and molecular biology procedures were performed at the VCU – Massey
Cancer Center Molecular Biology Core Facility, supported, in part, with funding
from NIH-NCI CCSG Center core grant (2-P30-CA-16059)
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Appendix B: Vector Map of Donor Vector
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rrnB T1 transcription terminator

Appendix C: Vector Map of Destination Vector
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Appendix D
Protocol for activation of MMP-1 by APMA
All solutions were freshly made on the day of performing the assay. MMP-1 present in
the conditioned media samples of U251MG and U87MG GBM cells that were stably
over-expressed with pIRES-MMP-1-AcGFP were treated with amino-phenyl mercuric
acid (APMA).
A stock solution of 10 mM APMA was prepared by dissolving 35.2 mg of
APMA in 0.1M sodium hydroxide (NaOH).

Tris-Triton-calcium (TTC) buffer was

prepared with final concentration of 50mM of Tris-HCL, 1mM of calcium chloride and
0.05% of Triton-X-100. 20 μl of conditioned media containing pro-MMP-1 from each
cell line was added to 200 μl of APMA (final concentration 4mM) and 280 μl of TTC
buffer. The reaction mix was incubated at 37°C water-bath for 24 hours.
For immunoblots, the conditioned media was used as it is at the end of incubation
for MMP-1 analysis. For treatment in cell cultures, the APMA was removed by dialysis
using Amicon Ultracentrigufal filter devices. Before addition of the reaction mix, the
filters were blocked with 100 μl of 1mg/ml of bovine serum albumin (BSA) for 30 min at
37°C. Thereafter, 500 μl of sterile PBS was added and the filters were centrifuged at
11,000 x g for 20 minutes at 4°C. The filters were inverted and spun briefly to remove
residual PBS and then dried.

The reaction mixture was added to these filters and

centrifuged at 11,000 x g for 20 minutes at 4°C to remove APMA. This was repeated so
as to remove the maximal amount of APMA.
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The concentration of proteins in

conditioned media was then analyzed using Biorad-DC protein assay. Equal amount of
protein was used for treatment of cells in culture.
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Appendix E
IGFBP2/3 does not get cleaved in the presence of activated MMP-1 from U251MG
MMP-1 overexpressing cells.

In the above figure, conditioned media from U251MG cells (Parentals P, Vector control
VC, MMP-1 over-expressers MMP-1 OE) was extracted and concentrated. MMP-1 was
activated using APMA and levels of IGFBP2/3 were examined. The data shows that
MMP-1 gets activated with APMA treatment. There is no affect on IGFBP-2/3 by
activated MMP-1. APMA treatment, by itself, resulted in molecular weight shift as seen
in P and VC samples.
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Appendix F
STAT-3 siRNA treatment in T98G cells leads to MMP-1 induciton

T98G cells treated with STAT3 siRNA show a significant knockdown of STAT3 (total)
protein levels. In these samples, MMP-1 expression was observed to be remarkably high
as compared to scrambled (scr) and oligofectamine (oligo) (transfection reagent) controls.
Lower panel figure shows that the levels of phospho- and total ERK do not change
among the three sample groups- Scrambled, Ogofectamine and STAT3 siRNA-treated
T98G cells.
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